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Abstract 
Introduction: Radiation retinopathy (RR) is a chronic progressive vasculopathy developing 
secondary to the impact of ionizing radiation to the retina. RR develops post radiation therapy 
using radioactive plaque to treat intraocular tumors. It is not possible to predict which patients 
will develop RR. Changes in retinal blood oxygen saturation and blood flow could predict the 
future onset of RR, thereby facilitating the use of treatment such as intra-vitreal anti-vascular 
endothelial growth factor (VEGF). 
Methods: Chapter 3 and 4: Total retinal blood flow (TRBF) and retinal blood oxygen saturation 
(SO2) was non-invasively measured in eleven healthy human volunteers using a novel and exact 
provocation technique (RespirAct) that allows the precise control of the end-tidal partial pressure 
of oxygen (PETO2). Between-visits repeatability and within-visit variability of TRBF and SO2 
measurements were assessed. Inner retinal oxygen delivery and consumption was calculated 
using Fick’s principle during stages of normoxia, hypoxia and hyperoxia. Chapter 5 and 6: 
Seventeen patients diagnosed with unilateral choroidal melanoma (CM) and eight patients who 
had developed unilateral ischemic RR were recruited from Ocular Oncology Clinic in the 
Princess Margaret Hospital, Toronto, Canada i.e. the only center all over Canada to treat CM 
patients with radiation therapy. The subjects underwent measurement of TRBF using a prototype 
methodology based upon Doppler Spectral Domain Optical Coherence Tomography (SD-OCT) 
and retinal vessel SO2 using a prototype Hyperspectral Retinal Camera (HRC), following pupil 
dilation with 1% tropicamide. In CM patients, the retinal hemodynamic parameters were studied 
in both eyes, before, 3months and 6months post 
125
Iodine plaque brachytherapy treatment. For 
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RR patients, the measurements were taken once in both eyes after confirming the ischemic 
changes by wide-field fluorescein angiography. 
Results: Chapter 3 and 4: When the arterial PETO2 (end-tidal partial pressure of oxygen) was 
increased from baseline (PETO2=100mmHg) to 200 and 300mmHg, the TRBF significantly 
reduced (p=0.020) from 44.60 μL/min (+8.9) to 40.28 μL/min (+8.9) and 36.23 μL/min (+4.6), 
respectively. Retinal arteriolar SO2 (SaO2) did not show any significant change during PETO2 of 
200 and 300mmHg, compared to baseline. However, retinal venular SO2 (SvO2) significantly 
increased (p<0.000) from 57.2% (+3.9) to 61.3% (+3.6) and 62.0% (+3.4) during PETO2 of 200 
and 300mmHg, respectively, compared to baseline. Lowering the arterial PETO2, from baseline to 
80, 60 and 50mmHg, TRBF significantly increased (p=0.040) from 43.17 μL/min (+12.7) to 
45.19 μL/min (+5.5), 49.71 μL/min (+13.4) and 52.89 μL/min (+10.9) with simultaneous 
reduction in the SaO2 and SvO2 from 99.3 % (+ 5.8) and 56.3% (+ 4.2) to 95.6% (+ 5.1) and 52.5 
(+ 4.1), 89.6% (+ 2.8) and 49.5% (+ 2.9), 83.3% (+ 3.9) and 45.0 % (+ 6.1), respectively 
(p<0.000). The group mean coefficient of repeatability (COR) for the retinal blood SaO2, SvO2 
and TRBF were 18.4% (relative to a mean effect of 104.4%), 15.2% (relative to a mean effect of 
60.3%), and 21.8 μL/min (relative to a mean effect of 44.72 μL/min). The overall coefficient of 
variability (COV) for SaO2, SvO2 and TRBF measurements were 4.7% and 6.9%, and, 15.1% 
respectively. The inner retinal oxygen extraction was calculated as 3.64 mLO2/min/100g tissue in 
humans. Chapter 5: The average TRBF in the eye with RR was significantly lower compared to 
the fellow eye (33.48 + 12.73 µL/min vs 50.37 + 15.26 µL/min; p = 0.013). The SaO2 and SvO2 
was higher in the retinopathy eye compared to the fellow eye (101.11 + 4.26%, vs 94.45 + 
5.79%; p=0.008) and (62.96 + 11.05% vs 51.24 + 6.88%, p=0.051), respectively. Chapter 6: Out 
  vii 
of 17 CM patients recruited, 2 patient data was excluded due to poor image quality, and 3 others 
were lost to follow-up. During the six month follow up period, one person developed RR.  The 
SaO2 measurement was found to be significantly increased (p=0.026) from 94.4 % (+7.9) to 
98.9% (+8.8) and 100.6 % (+6.4), respectively during 3 and 6 month follow up post 
125
Iodine 
plaque brachytherapy compared to before treatment.  
Conclusions: Chapter 3: Our study demonstrated significant changes in retinal blood SO2 and 
TRBF during systemic changes in arterial PETO2. The variability in TRBF measurements may 
reflect the impact of subjective assessment in venous area estimation as well as Doppler signal 
strength differences between visits. One needs to note that, a common clinical test such as visual 
acuity measurement also has a reported variability of up to ±0.15 logMAR (or + 8 logMAR 
letters), relative to a mean effect of 0.017 logMAR (+ 4.2 letters), yet it is still being utilized as a 
useful clinical tool. The Doppler SD-OCT and HRC offer a quantifiable and repeatable technique 
of assessing retinal hemodynamics. Minimizing subjectivity in terms of blood flow analysis as 
well as correcting imperfections in the optics design of the HRC could possibly improve the 
repeatability of TRBF and retinal blood SO2, respectively. Chapter 4: Oxygen extracted from the 
inner retinal vessels remains unchanged during safe levels of systemic hypoxia and hyperoxia. 
Chapter 5: The effect of ionizing radiation has an impact on the TRBF and retinal blood SO2, 
clinically presenting similar to a rapidly developing diabetic retinopathy. The results show an 
altered retinal vascular physiology in patients with radiation related retinopathy. Chapter 6: 
125
Iodine brachytherapy significantly increases the retinal arteriolar blood SO2, suggesting 
improved retinal tissue perfusion in the treated eye. It is interesting to note that one patient 
developed RR in this six month period. About a 20% increase in retinal arteriolar and venular 
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blood oxygen saturation was observed in this patient, 6 month post brachytherapy compared to 
pre-treatment value. In order to predict who will develop RR following brachytherapy, it is 
important to follow up rest of the eleven subjects to measure SO2 and TRBF during 12 and 18 
month period or until they develop retinopathy. This will be a future work of interest, to recruit 
even large number of CM patients in a longitudinal approach. Only then a pattern or model for 
predicting RR in terms of SO2 or TRBF measurements could be established. The study examines 
the early effects of brachytherapy on retinal hemodynamics. 
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 1 
 Introduction Chapter 1
1.1 The retinal vasculature: Blood supply and drainage 
The central retinal artery (CRA), a branch of ophthalmic artery, enters the eye via optic nerve 
head and supplies the inner retina.  The CRA then gives rise to four main branches: The 
superior, inferior, temporal and nasal retinal arterioles and these arterioles supply each 
quadrant of the retina.
1
 Retinal arterioles usually have a capillary-free zone running parallel 
to the course of the vessel where the oxygen content of the tissue is thought to be higher due 
to free diffusion. Whereas, venules are surrounded by slightly less pronounced oxygen 
enriched zone compared to arterioles.
2
  
The retinal capillaries are most dense in the center of the retina and eventually taper in 
density towards the periphery and around the perifoveal area, which surrounds the foveal 
avascular zone.
3
 The blood from retinal capillaries is drained via the retinal venules into the 
central retinal vein (CRV). Upon exiting the optic nerve, the CRV drains into either the 
ophthalmic vein or directly into the cavernous sinus (Figure 1.1).
1,4 
 
1.2 Structure and arrangement of retinal vessels 
The retinal vessels are arranged in a way that the major retinal artery and vein remain within 
the retinal nerve fiber layer and ganglion cell layer, whereas the arterioles and venules extend 
deeply to form the major capillary network. These networks thin as they extend themselves 
towards retinal periphery.
3
  
The walls of the major retinal arterioles are made up of five to seven layers of smooth muscle 
cells, which control the contraction and relaxation of vascular lumen. The smooth muscle 
cells are surrounded by a basal lamina containing collagen, which anchors the blood vessel to 
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the surrounding tissue. The endothelial cells lie between the smooth muscle layer and 
circulating blood.
5
 After branching, the number of layers that comprise the vessels 
diminishes into just one or two in the peripheral retina.
2
  
The anatomical arrangement of the retinal circulation has very important clinical 
implications. Due to the high metabolic demand, uninterrupted blood supply from both the 
choroidal and inner retinal circulation is essential; loss of either of those could impact the 
retinal function substantially. Also, the proximity of arterioles and venules itself might affect 
one another, especially at the arterio-venous crossing points.
4
  
 
Figure 1.1 A cutaway drawing of the human eye showing the major blood vessels supplying the 
retina, choroid and anterior segment. Drawing by Dave Schumick. Reprinted with permission from 
Encyclopedia of the eye (Anand-apte 2010), Elsevier Books. 
 
1.3 Autoregulation 
Retinal vessels lack neural innervation. However, the blood flow is effectively regulated 
through various neurogenic, hormonal, metabolic and myogenic-driven feedback 
mechanisms. It is mostly the metabolic and myogenic mechanisms that regulate the inner 
retinal blood flow.
6
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1.3.1 Myogenic autoregulation 
The ability of a tissue to maintain blood flow at a constant level despite changes in perfusion 
pressure is known as myogenic autoregulation.
7
 Experimenters previously demonstrated this 
type of autoregulation by increasing and decreasing the perfusion pressure to study retinal 
vascular resistance. These studies illustrate that the retinal vessels are capable of regulating 
the blood flow over a substantial range of intraocular pressure and systemic blood pressure.
8,9
 
Myogenic autoregulation happens when vascular endothelial cells stretch or compress due to 
the changes in transmural pressure causing the vascular smooth muscle cells to depolarize or 
hyperpolarize resulting in constriction or dilation of vessels.
10,11
 
1.3.2 Vascular reactivity and metabolic autoregulation 
The regulation of blood flow through the action of local factors, such as changes in arterial 
blood gases, modulate the vessel tone through release of vasoactive factors by the vascular 
endothelium and/or surrounding neural tissue; this is referred as metabolic autoregulation.
11
 
The term ‘metabolic autoregulation’ can alternatively be referred to as ‘vascular reactivity’. 
Vascular reactivity is the magnitude of change in hemodynamics to stimuli such as oxygen 
(O2), carbon dioxide (CO2), light and glucose.  
As arterial blood gas concentration varies, the retinal circulation adapts to neutralize the 
change in the local environment by releasing endothelial-mediated factors to provide a 
constant supply of O2.
12
 These factors either relax the vascular tone or constrict it. Nitric 
oxide and prostacyclin are two of the vasorelaxing factors, whereas endothelin-1, angiotensin 
II, thromboxane-A2 and prostaglandin H2 are some of the vasoconstricting factors. 
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Extracellular lactate leads to the contraction or relaxation of the vessel wall according to the 
local tissue needs.
11,13,14 
1.3.2.1 Manipulation of blood gases: RespirAct 
Provocations with various mixtures of O2 and CO2 have been used to investigate retinal 
vascular reactivity in humans and in animals. By administering safe levels of O2 or CO2, there 
will be changes in the arterial partial pressure of oxygen (PaO2) and arterial partial pressure 
of carbon dioxide (PaCO2), respectively. Hyperoxia is an increase in arterial partial pressure 
of oxygen from baseline homeostatic levels. Studies have shown that retinal vessels react to 
hyperoxia by local constriction of arterioles, venules and capillaries; thereby reducing the 
retinal blood flow (RBF).
132,133 
On the other hand, hypoxia leads to an increase in RBF by 
decreasing the PaO2. Independently controlling both PaO2 and PaCO2 is almost unlikely by 
other studies, where a 100% O2 is administered or ~>90% O2 and ~5% CO2 is coadministerd, 
without clamping the PaCO2 for hyperoxic provocation.
132,134,135 
This might further reduce 
the PaCO2 concentration, which might impact the measured variables.
136 
The novel computer-controlled prospective gas targeting system (RespirAct, Thornhill, 
Toronto, Canada) used in our lab has overcome the above mentioned limitation by 
minimizing alterations by independently maintaining PaCO2 during changes of PaO2 or vice 
versa. It comprises a fresh gas reservoir and an expiratory gas reservoir. Each reservoir is 
connected to a face mask with separate one-way valves. The face mask covers the mouth and 
nose of the subject. In turn, the two reservoirs are inter-connected using a positive end-
expiratory pressure (PEEP) valve which allows subjects to breathe exhaled gas (i.e. rebreathe 
CO2-enriched gas) when the fresh gas reservoir is depleted (Figure 1.2).
137,138 The subject’s 
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minute CO2 production and O2 consumption, gas flow and composition entering the 
sequential gas delivery circuit (Hi-Ox
80
, Viasys Healthcare, Yorba Linda, CA) was attained 
using an automated gas flow controller which is connected to a computer. 
 
Figure 1.2 Schematic of a sequential rebreathing system. Reprinted with permission from Microvasc 
Res. 2005 May; 69(3): 149-155. 
1.3.3 Impaired vascular response in retinal vascular diseases 
Diseases affecting the retinal circulation also alter vasoregulation in humans. In diabetic 
retinopathy, structural alterations to the capillaries, increased permeability of vessel wall, and 
growth of new fragile blood vessels are some of the clinical features suggesting alterations in 
microcirculation. However, due to the progressive and long course of the disease, several 
undetectable vascular and neural damages might subtly occur before the clinical signs are 
revealed.  
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Impaired vascular reactivity in response to hyperoxia (i.e. increased blood gas oxygen 
concentration)
15,16
 and flicker have been reported in diabetic retinopathy. Several animal and 
human studies report reduced vasodilatory response prior to the appearance of overt clinical 
retinopathy.
17,18
 In sight-threatening disease such as glaucoma,
 
vascular dysregulation has 
been reported as an important factor contributing to the pathophysiology.
19,20
 It is the 
combination of biochemical, hemodynamic and hormonal factors that could possibly initiate 
the alteration in blood flow regulation before the prominent clinical signs develop.
21,22 
1.4 Vascular network of the choroid 
The choroid is posterior part of the middle tunic of the eye, located in between the retina and 
sclera. The choroidal circulation nourishes the iris, ciliary body, and outer retinal layers 
including the retinal pigment epithelium and photoreceptors.  The choroid receives 80% of 
all ocular blood, with the remaining 15% going to the iris/ciliary body and 5% to the inner 
retina.
4
  
The choroid receives its blood supply via the ophthalmic artery from the long and several 
short posterior ciliary arteries (around the optic nerve head), with the short posterior ciliary 
arteries, supplying the posterior choroid and the long posterior ciliary arteries supplying the 
anterior choroid and the iris and ciliary body (Figure 1.1). The vascular layers of the choroid 
are divided into Haller and Sattler layers, consisting large and small arterioles and venules, 
respectively. The choriocapillaries form a dense network of highly anastomosed capillaries, 
located posterior to Bruch’s membrane.2,4 Blood from the choroid drains through the vortex 
veins into the ophthalmic vein.
1
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Choroidal vessels are fenestrated, unlike those in the retina (Figure 1.3). The fenestrations 
make them highly permeable to proteins, contributing to high oncotic pressure, which 
facilitates the movement of fluids in both directions between the retina and choroid. Also, 
sympathetic innervation controls the blood flow and other physiological functions of the 
choroid. The most important function of the choroid is to provide blood carrying oxygen and 
nutrients to the outer retina. The choroidal blood flow is the highest per unit time and weight 
of any other tissue. The flow is maximal at the fovea and close to the optic disc.
4
  
The melanocytes present in the choroid impart a darker pigmentation
23,24 
in primates. The 
choroid is also thought to act as a heat sink thereby preventing heat damage to the tissues. 
The smooth muscle cells that line the vessels of the choroid are innervated by both divisions 
of the autonomic nervous system.
24
 These nerve fibers form dense plexuses around the 
vessels. Axon terminals are also found throughout the stroma that terminate on non-vascular 
smooth muscle, intrinsic choroidal neurons, and possibly other cell types. There are also 
primary afferent sensory fibers that project to the trigeminal ganglion through the ophthalmic 
nerve. In mammals, the pterygopalatine ganglion is the origin of the main parasympathetic 
input to the choroid.
24
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Figure 1.3 A diagram showing details of the retinal and choroidal vasculature and changes that occur 
at the level of the human fovea. Drawing by Dave Schumick. Reprinted with permission from 
Encyclopedia of the eye (Anand-apte 2010), Elsevier Books. 
1.5 Comparative physiology and regulation of retinal and choroidal 
perfusion 
Both the choroid and the retina are vital in supplying the metabolic needs of the eye. 
However, these two structures have very different hemodynamic properties. The retina has a 
much lower blood flow but a higher level of O2 extraction compared to the choroid.
2
 The 
choroid has strong central sympathetic control mechanisms and has less autoregulation 
capacity. The retina on the other hand, lacks sympathetic innervation and thus is controlled 
solely by autoregulation instead.
4
 Autoregulation in the retina is effective within a wide range 
of perfusion pressures.
2
 The retina also has mechanisms for the local modulation, or fine 
tuning, of retinal blood flow but the data is limited. In contrast to the retina, circulation in the 
choroid is controlled by extrinsic autonomic innervation. Sympathetic afferent nerves release 
noradrenaline which binds to alpha 1-adrenoreceptors on vascular smooth muscle cells 
ultimately decreasing choroidal blood flow. Conversely, parasympathetic efferent nerves 
release nitric oxide which causes an increase in choroidal blood flow. The choroid also 
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receives innervation from trigeminal sensory fibers which contain calcitonin gene-related 
peptide. Experiments suggest a myogenic and/or neuronal contribution to choroidal blood 
flow regulation during changes in perfusion pressure but data is limited. Studies have shown 
that when dark-adapted eyes were exposed to room light, choroidal blood flow increased. 
These changes in blood flow were reported in both the stimulated and the contralateral eye 
indicating that the choroidal response is under neuronal control. These changes in choroidal 
hemodynamics that occur during light and dark adaptation could contribute to passive 
dissipation of heat induced by light, suggesting that the choroid is important for the 
maintenance of stable temperatures in the outer retinal layers.
2
  
Several studies have reported the precise response of retinal vasculature to changes in the 
blood gas concentration
25,26
 as well as to light-dark transitions.
12,27
 In contrast to retinal blood 
flow regulation, the choroid shows less hemodynamic response to flicker stimulation and 
light stimulation.
24
  
1.6 Quantification of retinal and choroidal blood flow 
The eye provides a direct opportunity to non-invasively observe the retinal circulation, unlike 
any other organ in the body. Taking advantage of this, several techniques have been 
established to study retinal microvasculature. Unlike retina, the choroidal vascular bed is not 
readily visible for evaluation due to the complexity and variability in terms of its distribution. 
Instead, high resolution broad bandwidth light sources are being utilized for choroidal 
imaging. Several studies have reported impaired blood flow to play a key role in the 
pathogenesis of retinal vascular pathologies such as diabetic retinopathy,
15,21,28
 age related 
macular degeneration (AMD)
30,31
 and glaucoma.
19,29
 The technical advancement has evolved 
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recently with several non-invasive techniques to reliably and conveniently quantitate the 
“blood flow”, which may become an important outcome measure and potentially a biomarker 
 toward understanding the vascular pathophysiology. 
1.6.1 General hemodynamic principles underling blood flow measurement 
Early in 19
th
 century, Poiseuille’s law explained that the flow of fluid through rigid tubes is 
governed by the pressure gradient and resistance to flow. Accordingly, blood flow (Q) is 
directly proportional to the perfusion pressure (ΔP) and inversely proportional to the vascular 
resistance (R). 
𝑄 =
ΔP
𝑅
 …………………………………………………………………………………… (1.1) 
The difference between arterial and venous pressure is known as perfusion pressure. Whereas 
resistance (R) of flow is defined by the following equation 
𝑅 =
8𝐿𝜂
𝜋𝑟4
…………………………………………………………………………………… (1.2) 
Where, L is the length of the vessel, 𝜂 is the fluid viscosity and r is the radius of the vessel. 
Rewriting Poiseuille’s equation will inter-connect all the blood flow parameters as follows. 
𝑄 =
𝛥𝑃𝜋𝑟4
8𝜂𝐿
 ……………………………………………………………………………….. (1.3) 
The equation shows that, compared to vessel length and viscosity of fluid, small changes in 
radius could trigger significantly larger changes in flow to the tissue, because flow is related 
to the fourth power of radius.
32
 Though Poiseuille’s law primarily explains the flow of fluid 
through rigid tubes, blood flow through a vessel is different because of the elastic property of 
the vessel wall. Also, the blood might not always obey Newtonian characteristics since it is 
viscous. 
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The retinal arteriolar and venular walls have the ability to adjust their caliber, i.e. contract or 
relax causing larger changes in the flow, therefore referred to as “resistance vessels”. 
Whereas, the capillaries are small enough to allow a single row of red blood cells to pass 
through them, in order to make sure necessary metabolic exchange takes place for proper 
tissue function, the capillaries are called “exchange vessels”. 
1.6.2 Retinal blood flow 
1.6.2.1 Estimation from retinal vessel diameter 
Retinal blood flow is directly proportional to the square root of vessel diameter.
33
 It is 
interesting to know how the researchers from past have made an effort to measure retinal 
diameter, a surrogate for blood flow. An ophthalmoscope was in fact the first instrument used 
to assess the overall retinal health as well as to study the retinal vessel caliber.
34
 The 
invention of fundus photography later provided a direct measure of retinal vessel diameter.
35
 
High resolution and magnified (35x) fundus images were projected onto a translucent screen 
to get a measure of retinal vessel diameter. However, the larger size of the vessel has 
restricted the measurable diameter to 0.5 to 1.5 disc diameter (DD) from the optic disc 
margin.
36
  
The retinal vessel analyzer was developed approximately 20 years ago to measure blood 
vessel diameter under varying brightness profile, i.e. retinal blood vessel is imaged between 
420-620nm light. The difference in the absorption characteristic of erythrocytes compared to 
the background (which reflects the light) fundus is what is used to measure the vessel 
diameter.
37
 Diameter measurements alone do not provide a direct estimate of the blood flow, 
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instead combined blood cell velocity measurement using laser Doppler velocimetry would be 
more meaningful.  
1.6.2.2 Laser Doppler techniques 
The “Doppler” principle was discovered by Christian Doppler in 1842, following which a 
multitude of applications were proposed based on the Doppler shift theory to determine the 
velocity of moving objects.
38
 One significant application in science, which is utilized thus 
far, is measuring the moving red blood cell velocity.  
1.6.2.2.1 Laser Doppler Velocimetry (LDV) 
Light of a known frequency (f) reflected by the blood vessel wall remains the same unlike 
those reflected by the moving red blood cells, which are shown to exhibit a shift in frequency 
(Δf). 39 The difference in frequencies of reflected light is used to calculate the red blood cell 
velocity (Figure 1.4). This phenomenon is used in all the Doppler techniques mentioned 
below. 
In LDV, the absolute velocity is measured by finding both the angle between the incident 
light and the blood vessel as well as the reflected light and the blood vessel. The 
photodetector present detects the maximum frequency shift from the center of the blood 
vessel. A fast Fourier transform is then used to obtain the Doppler shifted power spectrum 
(DSPS). The cut-off frequency of the DSPS demonstrates the maximum frequency shift, 
which is used to calculate the centerline blood velocity.
39 
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1.6.2.2.2 Bidirectional Laser Doppler Velocimetry (BLDV) 
Unlike LDV, the BLDV is unique in the sense that it is able to measure the absolute velocity 
by utilizing two photo-detectors of fixed angular separation for velocity measurements.
39
 The 
Canon laser blood flowmeter (CLBF) utilizes BLDV technique to quantitate absolute flow 
velocity by simultaneous measurement of blood velocity and vessel diameter. The CLBF is a 
fundus-camera type device with two photo-detectors and two lasers. A red diode laser is used 
to measure absolute velocity and a green rectangular helium-neon laser measures vessel 
diameter. The light scattered by the red blood cells at the site of measurement is detected 
simultaneously via two photodetectors separated by a known, fixed angle. Therefore two 
Doppler shifted frequencies are measured. The differences in the two values are used to 
calculate the centerline velocity of red blood cells in absolute units.
40
 In addition to the 
assumption that the flow within a vessel of interest is ‘laminar’ in nature. The CLBF is also 
limited to acquire measurements from retinal vessels of diameter greater than 60µm.  
 
  
Blood vessel 
Red blood cells 
f 
f f’=f+∆f 
Figure 1.4 Diagrammatic illustration of "The Doppler effect" phenomenon. 
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1.6.2.2.3 Scanning Laser Doppler Flowmetry (SLDF) 
Bonner and Nossal
41
 in 1981 introduced a technique based on light scattering properties of 
tissue containing moving red blood cells, to measure the volumetric blood flow in the retinal 
and choroidal vasculature. Though the technique uses the principle of “Doppler shift”, the 
laser light is not focused on the major retinal vessel; instead the flow is measured from the 
optic nerve head away from the large vessels. Therefore, SLDF only measures the relative 
mean velocity and volume of blood flow in arbitrary units. The major limitation is that the 
obtained signal from the sampled tissue could be from both retinal and choroidal vasculature, 
unlike LDV where the signal is strictly from RBC’s within retinal blood vessel.20,42 
Confocal scanning laser tomography later incorporated SLDF in the form of the Heidelberg 
Retinal Flowmeter (HRF), to quantitate optic nerve head and retinal capillary blood flow.  
The word “Tomography” refers to imaging by sections, deep into the tissue through the use 
of near-infrared light. The technical detail of HRF is described elsewhere.
43,44
 Briefly, the 
retinal tissue is sampled at a rate of 4000Hz using a 790nm laser source. Fast Fourier 
transformation of recorded Doppler shifted frequencies yields the relative capillary flow from 
a 10 pixel x 10 pixel region of tissue. A major limitation to the HRF is that the measurement 
of flow in arbitrary units, unlike CLBF, which measures flow in absolute units. 
1.6.2.2.4 Doppler Spectral/Fourier Domain Optical Coherence Tomography (SD-/FD-OCT) 
Optical Coherence Tomography (OCT) is a non-contact and non-invasive high-resolution 
technique for imaging of tissue structures on a micron scale. Due to its ability to provide real 
time cross-sectional images of tissue in situ, it functions as a type of “optical biopsy”.45  OCT 
generates the cross sectional images of the tissue microstructure by measuring the echo time 
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delay and the magnitude of the reflected light with a Michelson-type interferometer and low-
coherence light.
46
  
The Doppler principle was incorporated within the OCT in late 90’s, in which the Doppler 
frequency shift was obtained by a spectrogram method, which used a fast Fourier 
transformation
47
 for flow velocity calculation. However, this technique had limitations in 
terms of sensitivity and imaging speed. Later, spectrometer based Fourier domain Doppler 
OCT was introduced with improved imaging speed, high spatial resolution and velocity 
sensitivity.
48,49
 Alongside the conventional OCT images, flow images were successfully 
generated by Doppler based OCT. In a laminar flow system, precise measurement of the flow 
velocity is determined using Doppler OCT. Fourier transformation of the resulting 
interference signal is performed to obtain flow velocities.  
Doppler based OCT measures either the change in frequency to calculate the Doppler shift 
due to moving red blood cells, or the phase change between sequential A-scans in order to 
provide increased sensitivity to small flows.
50
 To measure the total retinal blood flow 
(TRBF), the principle of Doppler effect is utilized where the frequency shift (∆f) from 
backscattered light is detected and simplified to: 
∆𝑓 =
−2𝑛𝑉𝑐𝑜𝑠𝛼
𝜆0
……………………………………………………………………………  (1.4) 
Where, V is the velocity of the moving particle, 𝜃 is the angle between the OCT beam and 
the flow, n is the refractive index of the medium, and 𝜆0 is the wavelength of the incident 
beam.  
Flow in single vein=average (Vmax/Pi*Doppler phase shift*sin (Doppler angle))*vessel area, 
Vmax is the maximum speed corresponding to Doppler phase wrapping limit. Flow from 
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individual retinal venules is then summed up to obtain the total volumetric blood flow at one 
time point using specialized software named Doppler Optical Coherence Tomography of 
Retinal Circulation (DOCTORC) (Figure 1.5).
48
 
Studies have demonstrated the use of color Doppler OCT measurements of blood flow in the 
human retina in vivo and in real time with high data acquisition rates.
51
 In order to measure 
flow accurately with Doppler techniques, it is also necessary to measure the geometry of the 
vessel and, in particular, the angle of the vessel with respect to the indent light beam, since 
this determines the degree of “Doppler shift”.  
In contrast to the conventional Doppler OCT mentioned above, the bidirectional-based 
Doppler FD-OCT is capable of measuring the absolute velocity independent of the Doppler 
angle between the incident light and the flow velocity vector. In this technique, light reflected 
from a blood vessel is imaged simultaneously by two spectrometers of known angular 
separation. Along with the vessel diameter measurements, this technique enables quantitative 
retinal blood flow measurement.
129
 Recently introduced three beam Doppler OCT offers the 
advantage of a precise determination of velocity vector irrespective of vessel geometry 
information to acquire total retinal blood flow.
52 
 
SD-OCT is limited in terms of maximal velocity measurement due to imaging speed and 
phase averaging effects.
53
 Also flow measurement is limited to the smallest vessel diameter, 
since capillary flow involves single red blood cell movement, rather than continuous fluid 
flow as occurs in major branch vessels.
54 
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Figure 1.5 A) Screenshot of image showing the OCT beam passing through the superior nasal portion 
of the pupil. B) En face view of SD-OCT image with DOCTORC identified vessel location (numbers) 
and type (red=artery; blue=vein). Grader compares fundus photo with OCT image to confirm vessel 
type. 
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1.6.2.3 Other RBF measurement techniques 
1.6.2.3.1 Measurement of leukocyte velocity 
One of the oldest techniques to semi-qualitatively measure the red blood cell velocity in the 
retinal capillaries is Blue field entoptic technique suggested by Vierordt in 1860.
55
 The principle 
relies on the psychophysical comparison of the speed of one's own leukocytes with that of the 
minimum and maximum speed of the simulated particles, while illuminating the retina with a 
430nm light. The absorption of blue light by moving red blood cells but not by the leukocytes is 
the key in quantitating the retinal capillary blood flow. Though non-invasive, the technique has 
limited application due to its subjective way of measuring blood flow.  
1.6.2.3.2 Invasive dye dilution technique 
Fluorescein dye is administered intravenously to obtain a rapid sequence of photographs to 
visualize the time it takes for the dye to enter and clear a retinal blood vessel. This technique is 
known as fluorescein angiography (FA). The mean difference in passage of dye between the 
venous and arterial side of the blood stream is calculated as “mean circulation time”.56 Though it 
provides some index of retinal circulation, blood flow as such could not be quantitated using this 
technique. However, the technique is widely applied in clinical ophthalmology. 
1.6.2.3.3 Color Doppler Imaging (CDI) 
B-scan ultrasonography of tissue structure combined with Doppler shifted frequencies of moving 
erythrocytes evolved as CDI. In terms of blood flow measurement, CDI only provides the mean 
flow velocity, which is calculated from the peak systolic and end diastolic velocity.
57
 However, 
the flow velocity beneath the Doppler threshold could not be determined due to poor Doppler 
angle or undetectable Doppler shifts.
42
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1.6.3 Choroidal Blood Flow (CBF) 
Compared to retina, choroid has enormous blood flow (approx. 40 times greater than retinal 
vasculature), higher oxygen tension and most interestingly, a fenestrated, flat and wide capillary 
network.
58
 This arrangement makes blood flow measurement technically difficult. Although the 
choroidal vascular bed cannot be directly visualized, several invasive and non-invasive 
techniques were developed to assess its circulation.
59,60,62,63,130
 Invasive techniques such as direct 
measurement from choroidal veins, labelled microspheres,
59
 and hydrogen clearance
60
 are all 
restricted to animal studies. But, few techniques are actually carried out in human eyes. 
1.6.3.1 CBF measurement in humans 
Measuring the pulsatility of the blood flow was one of the earliest efforts made to study CBF. 
This could be due to the fact that choroid supplies the majority of the eye; therefore techniques 
that measures the pulsatile component of flow possibly estimate the choroidal perfusion, 
independent of the reterobulbar or retinal circulation.
61
 Pulsatile ocular blood flow measurements 
using ocular blood flow tonography per se are however influenced by variation in ocular rigidity 
between individuals and by both retinal and choroidal circulations.
62
 Polak and Co-workers 
utilized laser interferometry technique to measure the pulsations of the eye fundus to estimate the 
pulsatility of the blood flow. A light of wavelength 783nm is reflected both at the front side of 
the cornea and the retina. The changes in the interference fringes during a cardiac cycle, is 
observed as a distance change between cornea and retina. The maximum distance change 
measured is called as fundus pulsation amplitude. This technique is used to measure CBF. The 
CBF is measured close to the fovea, within the foveal avascular zone which is devoid of retinal 
circulation.
130
 
  20 
The macular area of the eye is predominantly nourished by the choriocapillaries located 
underneath Bruch’s membrane of choroid. Riva and Co-workers63 reported the relative CBF in 
the foveal avascular zone, using laser Doppler flowmetry (LDF) non-invasively. LDF as 
explained earlier utilizes the Doppler principle to measures the red blood cell velocity. Since the 
fovea is devoid of retinal vessels, the achieved signal must be primarily from the 
choriocapillaries. However, the technique is not widely applied due to its high measurement 
variability.  
Several imaging technique such as indocyanine green angiography,
64
 laser targeted 
angiography,
65
 have increased the understanding of choroidal circulation to the next level but the 
quantification of CBF using such techniques are difficult. Povazay and Co-workers
66
 have 
proposed an ultrahigh resolution FD-OCT system which utilizes light of wavelength 1050nm to 
provide better visualization of choriocapillaries beneath retinal pigment epithelium. Despite the 
greater penetration depth and higher signal to noise ratio, the system has low sensitivity and poor 
image resolution.  
1.6.4 Summary 
Over the past few decades, the non-invasive measurement of blood flow has been a special topic 
of interest in retinal vascular physiology due to the fact that RBF disturbances have been 
reported in various retinal pathologies such as diabetic retinopathy,
15,28
 AMD
30,31
  and 
glaucoma.
19,20
 The development of Doppler technology has been a major breakthrough in terms 
of blood flow quantification non-invasively. Several OCT techniques such as Spectral/Fourier 
domain, phase resolved,
49
  have evolved that are promising tools to measure RBF in health and 
in diseased eyes.  
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 The recently emerging optical coherence angiography (OCA) does not require dye such as 
fluorescein to be injected as a contrast agent into the blood stream to evaluate the motion of 
erythrocytes with in the vessels. Instead, a high speed FD-OCT system incorporated OCA, 
provides both structural and functional information by providing multiple cross-sectional images 
at the same location where volumetric OCA detects the relative motion of erythrocytes, in 
seconds, non-invasively.
42,67
 Enhanced depth imaging OCT
68
 and dual-beam-scan OCA
69
 are 
built with higher sensitivity and greater penetration for enhanced visualization of choroidal 
vessels. However, measuring choroidal perfusion is questionable due to various anatomical and 
physiological variations of the choroidal vasculature such as complex arrangement of 
choriocapillaries, higher flow rate, and fenestrated capillaries compared to the retinal vascular 
bed. 
1.7 Blood oxygenation measurement 
Oxygen is transported to the tissues by an iron-containing protein present in the red blood cells 
called hemoglobin (Hb). Each Hb molecule can bind up to four molecules of O2. Depending on 
the saturation or desaturation of Hb with O2, it is referred as oxyhemoglobin (HbO2) or 
deoxyhemoglobin, respectively. Measurement of oxygen saturation (SO2) is basically defined by 
the percentage amount of Hb bound to the oxygen. 
SO2 =
𝐻𝑏𝑂2
𝐻𝑏+𝐻𝑏𝑂2
× 100 …………………………………………………………………… (1.5) 
In addition to homeostatic blood flow, the SO2 in blood defines the metabolic state of the 
tissue.
20
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1.7.1 Absorption characteristics of hemoglobin 
Measurement of the amount of light absorbed by a substance at a given wavelength is referred as 
the “extinction coefficient”. The main absorption component of blood is Hb, but the oxy and 
deoxy hemoglobin exhibit differing molar extinction coefficients at most wavelengths (Figure 
1.6). The wavelengths at which both Hb and HbO2 exhibit similar absorption characteristics are 
referred as isosbestic or oxygen insensitive wavelengths, whereas, the wavelengths at which both 
Hb and HbO2 exhibit different absorption characteristics are referred as oxygen sensitive or non-
isosbestic wavelength.
70
  
 
Figure 1.6 The molar extinction coefficients of deoxyhemoglobin (Hb) and oxyhemoglobin (HbO2) as a 
function of wavelength. Reprinted with permission, Eye (2011) 25, 309-320, Nature Publishing group. 
 
1.7.2 Retinal SO2 measurement: Invasive techniques 
Oxygen supply to the inner retina can be assessed by studying the partial pressure of oxygen 
(PO2). Earlier studies report the assessment of PO2 by inserting O2 sensitive electrodes into the 
retina,
71
 or through techniques such as phosphorescence quenching of palladium or ruthenium 
porphyrine.
72
 These techniques are invasive and almost impractical to be used in human eyes. 
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1.7.3 Non-invasive oxygen saturation measurement 
Spectrophotometric techniques are considered as one of the safest and promising tools to extract 
oxygen saturation in retinal blood non-invasively.
79-81,84
 The different non-invasive techniques 
developed are discussed below. 
1.7.3.1 Retinal photometric oximetry: Dual wavelength method 
Measurement of oxygen saturation in blood or tissue is referred as “oximetry”. In 1945, Drabkin 
and Co-workers
73
 demonstrated the applicability of Beer-Lambert law in determining the SO2 of 
blood. The Beer-Lambert law explains that for any given wavelength of light, its absorption is 
dependent on the extinction coefficient of the blood (ε), its concentration or hematocrit (c), and 
the distance (d) the light has to travel through the solution (path length): 
𝐼𝑇 = 𝐼𝑜10
−𝜖𝑐𝑑…………………………………………………………………………… (1.6) 
Where IT is the intensity of the transmitted light through a solution and Io is the intensity of 
incident light.
70
  
Light absorption of a solution such as blood is given by its optical density (OD) which is given 
as 
𝑂𝐷 = −𝑙𝑜𝑔10
𝐼𝑇
𝐼𝑜
………………………………………………………………………… (1.7) 
The different absorption characteristics of oxy and deoxy hemoglobin allows the non-invasive 
quantification of SO2 by spectral measurements.
74,75
 The ratio of optical densities at isosbestic 
and non-isosbestic wavelengths gives the optical density ratio (ODR), which is given as follows 
𝑂𝐷𝑅 =
𝑂𝐷𝑛𝑜𝑛−𝑖𝑠𝑜𝑠𝑏𝑒𝑠𝑡𝑖𝑐
𝑂𝐷𝑖𝑠𝑜𝑠𝑏𝑒𝑠𝑡𝑖𝑐
…………………………………………………………………… (1.8) 
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Although the instrument is reported to be sensitive to changes in blood oxygen saturation, 
various confounding factors such as the light scattering properties of red blood cells,
76
 fundus 
pigmentation,
77
 and vessel width,
74
 has a significant impact on the measured SO2. Also, the SO2 
values achieved depend on the values used for calibration of arterial and venular SO2 i.e. 96% 
and 54%, respectively.
78
 
1.7.3.2 Spectral Imaging 
The limitations of the dual wavelength method encouraged the development of a new imaging 
technique utilizing spectroscopy to analyze materials by means of acquiring and identifying 
spectral signatures of its constituents using multiple wavelengths. The spectral signature of a 
molecule defines the structure of a molecule, when imaged at a series of specific wavelengths. 
Spectral imaging generates a number of greyscale images at various wavelengths, thereby 
providing both spatial and spectral information (Figure 1.7).
79
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Figure 1.7 Illustrated principle of the hyperspectral imaging to generate spectral images of the retina. 
Reprinted with permission, Experimental Eye Research (2016); 146: 330-340. Elsevier. 
 
1.7.3.3 Multispectral Vs Hyperspectral approach 
A multispectral
80
 approach utilizes a number of non-contiguous wavelengths at large bandwidths 
apart, whereas hyperspectral imaging
81
 uses a large number of contiguous wavelengths at narrow 
bandwidths and provides higher spatial resolution. Both the approaches could provide 
transmission of the reflectance spectrum of each pixel within the image enabling the 
identification of molecules. The reflected light from the fundus is collected using a charge-
coupled device and subsequently processed and analyzed to detect the substances present based 
on the spectral signature of each pixel. These spectral techniques are based on the principle of 
Beer-Lambert law and the known absorption spectra of hemoglobin to measure retinal blood 
SO2. 
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A form of retinal oximetry using a hyperspectral retinal camera (HRC) incorporates a tunable 
laser source which allows the rapid access of specific wavelengths.
81,82
  The HRC system records 
a series of time-sequential images at a sequence of wavelengths onto a 2D detector array forming 
a stack or cube of hyperspectral data within a few seconds.  The tunable filters have no mobile 
parts, so the instrument is able to electronically tune into any particular wavelength. The fundus 
is sequentially illuminated using monochromatic light of predetermined range of wavelengths. At 
each wavelength, a 30° field-of-view of the posterior pole of the fundus is captured at high 
resolution (1.3 Megapixels). The filters are capable of delivering monochromatic light at a 
narrow bandwidth (FTMW = 2nm) and image acquisition occurs at a rate of 27 frames 
(wavelengths) per second.  
A spectral data cube obtained by the HRC needs to be pre-processed before it can be analyzed. 
The spectral data cube is first normalized for spatial and spectral variations in light source 
intensity and any background ‘noise’ generated  from the system optics is removed.  Next, each 
image of the data cube is spatially registered with the rest of the images in the stack to correct for 
any motion artifacts.
81
 A pre-processed data cube is then opened with an in-house Matlab (The 
Mathworks, Natick, MA) program.
 
An automatic vessel segmentation algorithm
131
 is then used 
to isolate the main vessel in the fundus image. The segmented vessel is further analyzed to 
determine the retinal blood SO2 (Figure 1.8). 
The challenges faced by these imaging techniques includes the longer acquisition time, weak 
fundus reflectance due to melanin pigment, and various artifacts from the imaging optics.
8 
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Figure 1.8 Color coded SO2 map of retinal arterioles and venules. A scale of 0% and 100% represent 
percentage of oxygen saturation across the retinal vascular arcade. 
1.7.4 Other retinal oximetry techniques 
Photoelectric oximeters utilize three wavelengths (589, 569 and 586nm) to compensate for the 
light scattering effect of red blood cells as reported in the dual wavelength model.  The optical 
density of the vessel at each wavelength is calculated from the estimated light transmission 
through the vessel using the average vessel and background fundus reflectance. The instrument is 
limited to measuring only a small portion of the retina.
76
  
A scanning laser eye oximeter using four diode lasers emitting wavelengths centered at 629, 678, 
821 and 899nm for retinal vessel oximetry was introduced.
83
 The main difference compared to 
the three wavelength model is the use of a horizontal polarizer in the system, which compensates 
for the errors induced by specular reflection in the vessel wall. Hardarson and Co-workers
78
 later 
developed a retinal oximeter which produces retinal images simultaneously at four wavelengths. 
100% 
0% 
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Tsuchihashi and Co-workers
 84
 came up with a Fourier incorporated spectral retinal imaging 
system comprising an interferometer coupled to a fundus camera and a digital camera, which 
collect the spectral cube of two dimensional retinal images. The influence of choroidal 
circulation on retinal tissue SO2 calculations is a drawback of this system. 
1.7.5 Choroidal oximetry 
Based on the principles adapted from Hickam
85
 and Beach
74
 for calculating retinal SO2, 
Broadfoot in 1961
86
 developed a spectrophotometric choroidal oximeter to non-invasively 
quantify SO2 of choroidal vessels in humans. The system had a fundus monitoring unit, light 
source of wavelength 650 and 805nm and an electronic system for signal processing and SO2 
calculation.
87
 The oximeter could only report choroidal SO2 of individuals with lightly 
pigmented fundus. Also, the reported optical density ratios of choroidal vessels were calibrated 
based on the previously reported retinal blood SO2 values, which is not appropriate due to the 
different optical properties of the two tissues.  Obviously the choroidal oximeter calls for 
modification and refinement to better establish a reliable choroidal SO2 measurement in future. 
1.7.6 Summary 
Retinal oxygen saturation disturbances have been reported in diabetic retinopathy,
28,88,89
 
glaucoma
90,91
 and retinal vessel occlusions.
92,93
 While invasive techniques are restricted to 
animal studies, the development of non-invasive SO2 measurement is a major breakthrough in 
terms of uplifting our understanding of retinal pathophysiology and might also help in early 
diagnosis. The retinal oximeters described above only quantify the SO2 of retinal blood; 
however, the recently introduced metabolic hyperspectral camera could quantitate the retinal 
tissue SO2.
82
 It allows the derivation of oximetric maps of the fundus from capillaries and optic 
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nerve head tissue in humans, with a short acquisition time of 3 seconds. One potential limitation 
is that the reported retinal tissue SO2 might as well be influenced from the underlying choroid 
which has a higher flow rate. Automation of retinal SO2 measurement, improvements in imaging 
technology, eye movement tracking facility are some of the upgrading which most likely is 
mandatory to improve the oximeter’s performance. 
1.8 Inner retinal oxygen distribution 
The retina is one of the highest O2 consuming tissues in the human body. It has multiple layers 
with different cell types and the surrounding vascular components are spatially separated. Due to 
the variable degree of vascularization across the different regions of retina, a delicate balance 
exists between the available oxygen supply and the consumption within the retina.
94
 Proper O2 
supply is vital in order to prevent the tissue from ischemic insult. Tissue hypoxia is thought to be 
an important factor in retinal diseases with a vascular component.
95
 On the other hand excess 
supply might also aggravate several pathogenic factors leading to cell death.
96
  
Measurement of O2 level within the retinal layers is known to be invasive and only possible in 
animal studies.  O2 sensitive microelectrodes are inserted into the eye to obtain higher resolution 
O2 tension measurements as a function of retinal depth. The oxygen distribution within the 
various retinal layers is not shown to be uniform in nature.
97
 One study recently reported the 
dominant O2 consuming retinal layers in rats as inner segments of the photoreceptors, the outer 
plexiform layer, and the inner plexiform layer.
98
 Since measuring retinal tissue O2 tension in the 
way mentioned above is impractical in humans, several non-invasive techniques have been 
developed to quantitate the amount of O2 saturated in retinal arteriolar and venular blood to get 
an idea of oxygen extraction in humans.
99,100
 Werkmeister and co-workers
99
 recently published a 
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more detailed mathematical model of translating the RBF and retinal blood SO2 values into total 
O2 extraction and oxygen extraction fraction (OEF) in humans. OEF is reported to be an 
important biomarker to quantitatively assess the adequacy of O2 supply for metabolism under 
physiological and pathological conditions.
101
  
1.8.1 Inner retinal oxygen extraction 
Oxygen delivery to the retina is derived from two factors, namely, RBF and O2 content of the 
arterial blood. The combination of these two factors could provide insight into the inner retinal 
oxygen extraction. The relationship of these two factors in determining O2 delivery and 
consumption of retinal tissue is given as follows. 
Retinal O2 delivery (DO2) = Blood flow * (SaO2*[Hb]*1.34 ml O2/gm Hb + 0.003ml O2/ (dLblood×mmHg)*PaO2) 
……………………………………………………………………  (1.9) 
Retinal O2 consumption (VO2) = TRBF * (CaO2 - CvO2)………………………………….…….. (1.10) 
Where SaO2 is the oxygen saturation of the retinal arteriolar blood, Hb is the hemoglobin 
concentration and PaO2 is the arterial partial pressure of oxygen. Approximately > 98% of O2 is 
bound to Hb in a healthy human, each gram of Hb binds to 1.34 ml of O2. The O2 solubility 
coefficient in human plasma is 0.003. The arteriovenous difference in oxygen content is given by 
CaO2 - CvO2. 
The ratio of arteriovenous O2 content difference and arterial O2 content is given as oxygen 
extraction fraction.
101
  
𝑂𝐸𝐹 =
CaO2 − CvO2
CaO2
……………………………………………………………………… (1.11) 
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1.8.2 Summary 
An alteration of retinal O2 delivery may result from an overall increase or decrease in metabolic 
demand by the retinal tissue. However, in healthy retinae, the existences of regulating 
mechanisms control the O2 supply and consumption by various mediating factors which are still 
a topic under research. These mechanisms become obvious by observing the retinal vessels under 
various provocative stimuli such as gas challenges, flicker, and light-dark transitions. For 
instance, during systemic hyperoxia, the retinal arterioles constrict to limit the blood flow in 
order to dampen the effect of increased oxygen consumption in the inner retina.
99,102
  Also, 
Palkovits and co-workers
100
 reported that the inner retinal O2 consumption remains unchanged 
during graded hypoxia, since the retinal vessels compensate for the decrease in oxygenation by 
vasodilation.  
1.9 RBF and SO2 in retinal vascular diseases 
A plethora of evidence suggests altered vascular regulation in diseases affecting retinal 
vasculature such as diabetic retinopathy, retinal occlusive diseases, AMD, and glaucoma.
28, 88-93
 
The transparency of the ocular media allows the direct visualization of retinal microcirculation 
non-invasively. Structural changes such as retinal arteriolar narrowing,
103
 vessel tortuosity,
104
 
and a smaller arterio-venous ratio
105
 have been reported in individuals with underlying systemic 
inflammation. Studies assessing the vascular reactivity of the retinal vessels to provocative 
stimuli including, hyperoxia, hypercapnia, light stimulation and changes in perfusion pressure 
also give meaningful insight on altered vasoregulation, which is considered as an early 
biomarker for diseases affecting retinal circulation. Lower blood flow
28,106
 and higher SO2
28,88,89 
were earlier reported in diabetic patients with non-proliferative retinopathy, suggesting a reduced 
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O2 uptake from the retina even in the early stages of the diseases.  Increased venular SO2 and 
lower arteriolar SO2 was reported in patients with primary open angle glaucoma and normal 
tension glaucoma, respectively, compared to controls.
107,108
  Another study reports a plausible 
relationship between reduced blood flow and visual field loss in glaucoma patients.
109
 These 
quantitative measurements were reported to be correlated with the functional changes in 
progressive diseases. 
The utilization of these novel tools to non-invasively quantitate RBF and SO2 might possibly 
facilitate our understanding of the vascular pathophysiology as well as promote early detection 
and possible treatment intervention in the future. 
1.10 Choroidal Melanoma (CM) 
Melanoma of the choroid arises from the pigment producing cells called melanocytes. Although 
melanoma could arise from other part of the uveal tract, such as iris and ciliary body, choroidal 
melanoma alone accounts for 80% of all uveal melanoma cases. CM is known to be the most 
important primary intraocular tumor in adults. Individuals with light colored iris, high amount of 
ultraviolet exposure are at most risk of acquiring this disease.
110
 In North America alone, 6 per 
million people or 1400 new cases of CM are diagnosed annually. The size and location of the 
tumor determines the type of treatment to be administered. The 5-year relative tumor related 
mortality for people with large choroidal melanoma of any size is almost 30%.
111
 
1.10.1 Pathophysiology 
CM arises from three distinct cell types known as spindle A, spindle B and epitheloid cells; of 
which the third type is most aggressive in nature with poor prognosis. The tumor appears as 
either darkly pigmented or amelanotic (Figure 1.9). As these tumors enlarge, they eventually 
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break through the Bruch’s membrane and gives rise to a characteristic mushroom configuration. 
It may also evolve as diffuse, bilobular and, multilobular in shape.  
 
Figure 1.9 Color photograph of a dome-shaped choroidal melanoma. 
As these tumors push against the retinal pigment epithelium (RPE), it deprives the outer retinal 
layers from normal choroidal circulation, leading to ischemia, RPE atrophy, drusen, and 
localized RPE detachment.
112
 CM is highly metastatic in nature. Its metastatic potential depends 
on the histopathologic aggressiveness of the tumor cells. Due to the absence of lymphatic vessels 
in the eye, the common site of tumor metastasize is reported as liver.
113 
1.10.2 Treatment 
Various factors such as tumor size, location, extent, patient’s age and general health all play an 
important role in determining the treatment type needed. Some of the common treatment options 
are briefed below. However, tumors with large tumor base and size often require enucleation.
111
   
1.10.2.1 Radiation therapy 
External beam radiation therapy (EBRT) and Brachytherapy are the two main radiation 
treatments offered to treat CM.
114
 In Brachytherapy (also known as episcleral plaque 
radiotherapy), radioactive seeds containing Iodine-125 or Ruthenium-106 are surgically inserted 
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at the tumor base using a episcleral plaque.
115,116
 This plaque is then removed from the eye, once 
the required dose is delivered to kill the tumor cells. Compared to enucleation, brachytherapy is 
preferred treatment of choice for it has the possibility of salvaging the eye. 
In EBRT, the radiation treatment is delivered from outside the eye. This treatment is preferred 
when the tumor location is close to optic nerve head, where the brachytherapy is difficult to 
perform.
115
 Although radiation therapy is shown to be an excellent treatment for most CM 
patients; it comes with its own risks and side effects. Possible side effects of treatment include 
radiation retinopathy (RR), optic neuropathy, increased ocular pressure and poor vision.
117-119
 
1.11 Effects of ionising radiation on retinal vasculature 
Radiation treatment is known to be a treatment of choice for small to medium sized choroidal 
melanomas. Though salvaging the eye seems to be unique in this treatment, vision deterioration 
is often unavoidable due to developing retinopathy post treatment. RR is a vision-threatening 
complication after EBRT or plaque brachytherapy of the eye and surrounding tissues.
120
  
Endothelial cells lining the blood vessel wall have been shown to go through radiation insult, 
followed by capillary occlusion.
121
 The vascular pathology involved is reported as microvascular 
in origin including vascular occlusion, incompetence and vasoproliferation. One of the early 
microvascular changes observed are microaneurysms occurring singly or in small clusters,
122
 
followed by focal capillary occlusion. Irregular dilation of the neighboring microvasculature is 
also noted as an early change in retinal microvasculature. The affected vessels typically remain 
competent early in the course of disease.
123
 Starting as a small, subtle localized retinopathic 
lesion, the microvasculopathy aggravates further as an increased number of microaneurysms, 
capillary bed collapse and development of telangiectatic-like channels. These channels are a 
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“hallmark” of RR and are likely due to altered local hemodynamics and radiation induced 
changes in the capillary wall. With higher doses of radiation, more exaggerated and diffuse 
patterns of capillary closure and dilatation are observed.
122,123
 
RR is classified as more common non-proliferative type or severe proliferative type. Non-
proliferative changes include the presence of microaneurysms, cotton-wool spots, hard exudates, 
hemorrhages, retinal edema and/or vascular sheathing. Proliferative retinopathy is characterized 
by the presence of retinal or disc neovascularization, vitreous hemorrhage and retinal 
detachment. These signs are typically observed in the posterior pole. 
The rate of development of retinopathy can range from months to years after radiation treatment. 
It is almost impossible to predict who will develop RR post radiotherapy. The first signs of RR 
occur months to years after the exposure to radiation.  Brown and Co-workers
124
 reported an 
average of 14.6 months for RR to develop following radioactive plaque therapy.  Another study 
reported that RR developed after a mean period of 18.7 months after external beam 
radiotherapy.
125 
The key factors that determine the development of RR are the radiation dose, 
tumor size and location.
120
 The Collaborative Ocular Melanoma Study (COMS) reported that RR 
was seen in 90.7% of eyes 8 years following Iodine-125 brachytherapy.
126
 The long-term 
complications of RR are a consequence of the inner retinal ischemia and vascular incompetence 
that develops due to the changes in vasculature. In advanced RR, blindness and pain can present 
as a result of radiation-induced ischemia or neovascular glaucoma.
117 
1.11.1 Pathogenesis of RR 
Radiation exposure damages the cells, organelles and DNA of the tumor cells. However, the 
surrounding healthy retinal tissue also seems to get affected indirectly. Endothelial cells are 
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reported to exhibit changes both structurally and functionally following radiation insult. Ionizing 
radiation disturbs chemical bonds in molecules, forms toxic-free radicals and damages the 
DNA.
127
 As a result, the retinal vessels start showing similar changes as irradiated tumor vessels. 
Fluid and proteins leak into the retina causing edema and hard exudates. The decompensation of 
the retinal vessels results in microaneurysms and intraretinal microvascular abnormalities. These 
microaneurysms can develop into dot and bot hemorrhages. The appearance of the fundus 
strongly resembles that of diabetic retinopathy except that there are generally fewer 
microaneurysms seen with RR.
121
 Later in the course of RR, the features reflect vascular 
occlusion at various retinal and choroidal layers. These changes present as cotton-wool spots and 
venous beading. Sometimes occlusion of the larger retinal vessels occur which can cause retinal 
arterial and vein occlusions. Proliferative RR can occur when retinal ischemia leads to 
neovascularization of the retina or optic disc.
125 
1.11.2 Treatment and Management 
The treatment options for RR are similar to those administered to other retinopathies such as 
diabetic retinopathy, retinal artery and vein occlusions.  Anti-Vascular Endothelial Growth 
Factor (VEGF) agents and intravitreal steroid injections are few of most preferred treatment 
choice. However, other forms of treatment such as hyperbaric oxygen treatment, and oral 
pentoxifylline are still under research.
128
 Regardless of the type of irradiation, larger tumors 
make for a poorer prognosis as the amount of radiation delivered to all surrounding ocular 
structures is higher.  
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1.12 Summary 
The retina is a tissue with an extremely high metabolic demand. The transparency of the tissue 
itself offers direct visualization of its microvasculature. Taking advantage of this, many 
techniques were introduced and continue to be developed to non-invasively quantitate the 
volume of blood/O2 delivered to this tissue through the inner retinal vasculature. Advances in 
technology have allowed for non-invasive techniques of measuring blood flow and oxygen 
saturation in a more efficient and comfortable way compared to invasive methods.  
RBF and SO2 remain two important factors that reflect the dynamic aspects of oxygen 
metabolism in the retina.
80
 By knowing these two parameters, net oxygen delivery to the retina 
could be derived non-invasively. Retinal O2 metabolic rate is a candidate parameter to 
understand the functional status of the retina in health and disease. A vast majority of retinal 
vascular pathologies report tissue hypoxia as a disease building mechanism towards sight 
threatening impairment.  
There are quite a few studies that report effect of ionizing radiation to the retinal vasculature. 
The damage to retinal vessel makes the tissue deprived of oxygen leading to ischemia. The 
morphological retinal changes associated with RR resemble those of diabetic retinopathy but the 
rate of progression is far more rapid than diabetic retinopathy. Though the radiation seems to 
harm the tissue in one way, it is the preferred treatment of choice for CM. Retinal SO2 could be a 
useful biomarker for ischemic related retinopathies such as diabetic retinopathy and retinal vessel 
occlusion. This ultimately offers a potential to allow early intervention, especially at the 
appropriate time when needed. 
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By utilizing the advantages of spectral imaging techniques we are able to detect and quantify 
molecular spectral absorbance profiles in the retinal tissue. Oxy- and deoxy- hemoglobin are well 
established molecules in terms of their spectral characteristics and quantification in the retina is 
more relevant to understand the retinal vascular physiology in health and disease. By studying 
how the retinal microcirculation reacts to radiation exposure in terms of changes in oxygenation 
could improve our understanding of this sight-threatening vascular pathology. 
  
  39 
 Rationale Chapter 2
The understanding of vascular pathophysiology underlying sight threatening ocular diseases such 
as diabetic retinopathy, retinal vascular occlusive diseases, AMD and glaucoma has significantly 
improved due to the advances in non-invasive imaging technology. Quantification of retinal 
blood oxygen saturation, per se, was once restricted in humans,
1-3
 is now possible non-invasively 
by utilizing spectral imaging
4,5
  and SD-OCT techniques.
8
 The direct visualization of retinal 
microvasculature offers the potential for newer techniques to develop, which could eventually 
unveil the hemodynamic changes in retinal vascular diseases.  
In contrast to flash or snap-shot hyperspectral retinal cameras, the retinal oximeter utilized in our 
lab constructs a spectral data cube based on non-flash ultra-high speed sequential imaging. There 
is evidence to suggest that using flash illumination may artificially alter the measured retinal SO2 
values.
21
  On the other hand sequential imaging is more susceptible to motion artifact, however, 
the HRC used in our lab has a high frames per second imaging capability to minimize this effect. 
Several studies in the past have reported altered RBF and SO2 in retinal vascular diseases. 
Retinal blood velocity, decades back was only measured from a single retinal vessel. Together 
with the vessel diameter measurement, the flow was then calculated in absolute units for that 
particular vessel.
6,7
 Whereas today, the blood flow can now be quantitated from all the retinal 
vessels passing in and out of the optic nerve head utilizing Doppler incorporated OCT.
8,9
  This 
negates the limitations reported previously with other laser Doppler techniques such as laser 
Doppler velocimetry, color Doppler imaging and scanning laser Doppler flowmetry.
10-12
 
Retinal perfusion changes in radiation induced retinopathy have not been studied as much as 
other retinal diseases such as diabetic retinopathy, retinal vascular diseases or glaucoma.  The 
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primary vascular events to radiation insult are endothelial cell loss and capillary closure.
13,14
 This 
imposes a burden on retinal metabolism due to progressive changes in retinal microvasculature. 
Various signs such as microaneurysms, hemorrhages, and cotton wool spots develop as a result 
of developing retinopathy.
15,16
 It is impossible to know who will develop RR following plaque 
brachytherapy for CM. Studying retinal oximetry changes could predict the future onset of 
radiation retinopathy and would permit vasculopathy treatment such as anti-VEGF therapy and 
thus could salvage the eye from this sight threatening condition. 
Altered RBF and oxygenation are previously reported in diabetic patients in the very early stages 
of retinopathy.
17-19
 A possible relationship between retinal hypoxia and vascular pathogenesis 
has been reported in diabetic retinopathy, which further provokes neovascularization and retinal 
edema.
20
 Similar pathogenies may be expected in RR as well, considering the fact that both the 
conditions show similar clinical signs, except that in RR, endothelial cells are the prime site of 
damage. The progression of RR is much faster than typically seen in diabetic retinopathy. 
Whether or not a person will develop retinopathy following brachytherapy for CM is an 
interesting question to answer. 
2.1 General Objective 
The general objective of this work is to investigate changes in retinal hemodynamic parameters 
such as blood flow and oxygenation, to facilitate better understanding of the vascular 
pathophysiology of radiation induced retinopathy. 
This body of work will determine the between-visits repeatability and within-visit variability of 
retinal blood flow and SO2 measurements using Doppler SD-OCT and HRC, respectively, under 
varying blood gas perturbations. The study will also investigate changes in retinal blood SO2 and 
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TRBF in patients diagnosed with RR, post 
125
iodine brachytherapy. The study also compares the 
before-after changes of these early biomarkers in CM patients who underwent plaque radiation 
treatment, to predict the earliest changes. 
2.2 Specific Aims 
1- To validate and calibrate the Doppler SD-OCT derived TRBF and HRC derived SO2 of major 
retinal vessels in human volunteers using a novel and exact provocation methodology 
(RespirAct) that has been proven to allow the precise control of the end-tidal partial pressure of 
oxygen. Between visits repeatability of the TRBF and retinal blood SO2 were also studied 
(Chapter 3). 
2- To determine the inner retinal oxygen delivery and consumption during normoxia, hyperoxia 
and hypoxia in healthy humans (Chapter 4). 
3- To investigate retinal blood flow and oxygen saturation changes in patients diagnosed with 
retinopathy following plaque radiation treatment to treat choroidal melanoma (Chapter 5). 
4- To evaluate pre- and post- changes in TRBF and retinal blood SO2, in patients who underwent 
125
Iodine plaque brachytherapy, to treat choroidal melanoma (Chapter 6). 
2.3 Hypotheses 
1- Retinal blood flow and oxygen saturation measurements performed under safe levels of 
hypoxia and hyperoxia will be repeatable in healthy adults (Chapter 3). 
2- Retinal O2 consumption will increase and decrease during safe levels of hypoxia and 
hyperoxia, respectively (Chapter 4). 
3- In patients diagnosed with RR, retinal blood flow and oxygen saturation will be altered in the 
major retinal vessels (Chapter 5). 
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4- Post radiation therapy, the treated eye will exhibit decreased TRBF and increased retinal 
blood SO2 as a treatment response (Chapter 6). 
2.4 Summary 
The novel prototype instruments utilized in this study are unique in the sense that the Doppler 
SD-OCT is only available in two labs world-wide including our lab; and the HRC for retinal 
blood oximetry is not available for research elsewhere in the world except Hudson lab. These 
two methodologies are validated using a reliable and highly reproducible technique for the 
provocation and quantification of vascular reactivity of the retinal vasculature. The ability of the 
prototype instruments to detect changes in arterial partial pressure of oxygen was investigated in 
healthy human volunteers. The computer-controlled gas sequencer is unique compared to other 
rebreathing units utilized elsewhere, in the way it independently targets end-tidal gas 
concentrations, and in particular, end tidal O2 concentrations and end-tidal CO2 concentrations, 
independent of one another and also independent of minute ventilation.
22,23 
The combination of 
computer-controlled gas sequencer that allows the implementation of precise combinations of O2 
and CO2 concentrations as vaso-active provocative stimuli, and the quantification of retinal 
blood flow and oxygenation provides much reproducible data. The novel application of these 
established technologies in studying the retinal hemodynamic changes in radiation induced 
retinopathy is studied for the first time. This work also evaluates the ability of hyperspectral 
retinal imaging to non-invasively quantify oxygen saturation disturbances in the retinal blood 
post-brachytherapy for CM, prior to the development of clinically visible retinopathy. This could 
provide an opportunity for early intervention for developing vasculopthy using anti-VEGF 
agents, as well as, provide an in-sight into the pathogenesis of RR. 
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 Inter-Visit Repeatability of Retinal Blood Oximetry and Chapter 3
Total Retinal Blood Flow under Varying Systemic Blood Gas 
Oxygen Saturations 
Kalpana Rose; Susith I. Kulasekara; Christopher Hudson 
Investigative Ophthalmology & Visual Science January 2016, Vol.57, 188-197. 
doi:10.1167/iovs.15-17908 
3.1 Introduction 
The retinal blood vessels carry the necessary O2 and other essential nutrients to the retina, in 
order to meet its huge metabolic demand.
1
 The delivery of O2 to the retina is determined by 
factors such as RBF and the arterial / arteriolar blood O2 content.  The efficient regulation of 
blood flow and O2 supply is vital to the retina in order to preserve vision. Therefore, the current 
study focuses on measuring the amount of blood flowing through the retina and the O2 dissolved 
in those blood vessels, in order to explain how the retina regulates overall blood and O2 supply. 
The retina regulates blood flow in response to the local tissue demand. Despite the absence of an 
intrinsic sympathetic nerve supply, RBF can be maintained constant over a wide range of 
perfusion pressure.
2-6
 This process is termed as “autoregulation”. The smooth muscle layer and 
the endothelial cells lining the blood vessel wall plays a significant role in regulating the blood 
flow by enabling the constriction and dilation of the blood vessel, thereby decreasing and 
increasing the flow, respectively. The autoregulating ability of the retinal blood vessels was 
previously reported by many authors.
7-15
 Several studies have demonstrated changes in retinal 
vessel diameter, velocity and flow to various provocative stimuli such as O2, CO2, and flicker in 
healthy
12,16,17 
and diseased cohorts.
18-20,25
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Hypoxia, an decrease in O2 concentration, has been shown to vasodilate the retinal vessels.
21,22
 
Conversely, an increase in O2 (hyperoxia) leads to vasoconstriction.
8,13
 These changes occur to 
maintain constant O2 delivery and to meet every day metabolic demands of the retina.  
Dysregulation of retinal vasculature is considered to be a precursor of major retinal diseases.
23,24
 
Impaired retinal vascular reactivity has been reported in diabetic retinopathy,
18,19
 glaucoma,
25
 
and also in smokers.
26,27
  
The interest to develop imaging techniques to quantitate non-invasive RBF started in early 
1970’s,28 when the first laser Doppler instrument was introduced to measure retinal red blood 
cell velocity. The application of Doppler technology in retinal imaging further evolved with the 
introduction of Canon laser blood flowmeter,
29-31
 a technique that utilizes bi-directional laser 
Doppler velocimetry, and now as the functional extension of OCT, i.e. Doppler SD-OCT
32,33 
and 
bi-directional laser Doppler OCT.
34
 Though the blood flow measurement, per se, may facilitate 
better understanding of major retinal diseases including glaucoma, diabetic retinopathy and 
AMD; more meaningful conclusion could be drawn if retinal blood SO2 could also be measured. 
The introduction of spectral imaging techniques to detect and quantify molecular spectral 
absorbance profiles in retinal tissue is a major advancement in the field of retinal imaging. The 
HRC offers the potential to non-invasively quantify SO2 disturbances in the retina. A plethora of 
evidence suggests retinal blood SO2 changes in diseased eyes.
35-37
 The novel application of 
Doppler SD-OCT and HRC might offer the potential for early intervention, and in-sight into the 
pathogenesis of retinal pathologies.
33,38
  
In this study, the SO2 values of major retinal vessels and the TRBF are validated and calibrated 
in human volunteers using a novel and exact provocation technique (RespirAct) that allows the 
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precise control of the PETO2 to induce safe levels of hypoxia and hyperoxia. This technique 
uniquely targets exact PETO2 and stabilizes the PETO2 while maintaining isocapnia, irrespective of 
the individual participants’ ventilatory response.39,40 Also, the study inter-relates TRBF and 
retinal blood SO2 in healthy individuals. PETO2 was changed as defined by a series of step 
changes in inhaled O2 and the reproducibility of SO2 and TRBF values was assessed during 
normoxic conditions. 
3.2 Materials and methods 
3.2.1 Sample 
This study was approved by the University of Waterloo Office Of Research Ethics, Waterloo, 
and by the University Health Network Research Ethics Board, Toronto. One eye of 11 healthy 
subjects, mean age 33.36 yrs, SD 6.03 yrs was recruited. All subjects had a logMAR (logarithm 
of minimum angle of resolution) visual acuity of 0.0, or better. All participants were young, 
healthy and non-smokers. Exclusion criteria included any refractive error > + 6.00 Diopters 
sphere and / or + 1.50 Diopters cylinder, intra ocular pressure > 21mm Hg, treatable respiratory 
disorders (e.g. asthma), systemic hypertension, cardiovascular disease, diabetes, endocrine 
disorders, medications with known effects on blood flow (e.g.-anti-hypertensive, medications 
with activity at autonomic receptors, smooth muscles, or those affects nitric oxide release.), 
family history of glaucoma, or a history of any ocular disease. All the participants were asked to 
abstain from caffeine, red meat and alcohol for 12 hours and avoid rigorous exercise about 1 
hour prior to their study visit. Informed consent was obtained from each subject after a thorough 
explanation of the nature of the study and its possible consequences, according to the tenets of 
the Declaration of Helsinki. 
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3.2.2 Study visit 
The study comprised of two visits, with two sessions each visit. During each visit, TRBF and 
SO2 measurements were acquired under conditions of normoxia, hyperoxia and hypoxia. The 
order of hyperoxia and hypoxia was altered across two visits separated by a week interval. Each 
visit lasted for approximately 3 hours. 
3.2.3 Instrumentation 
3.2.3.1 Doppler Spectral Domain Optical Coherence Tomography (SD-OCT) 
The novel prototype Doppler SD-OCT utilizes the principle of “Doppler effect” to non-
invasively quantitate the TRBF. The commercially available Optovue RTVue OCT (Optovue, 
Inc., Fremont, CA, USA), is a spectrometer-based OCT system, consist of a super luminescent 
diode with a center wavelength of 841 nm and a bandwidth of 49 nm. The axial resolution is 5.6 
µm in tissue and transverse resolution is 20 µm. The scan protocol for TRBF measurement 
consist of double circular Doppler scans in the form of two concentric rings of diameters 3.40 
mm and 3.75 mm centered on the optic nerve head, transecting all branch retinal arterioles and 
venules.
32
 A total of six scans were obtained and averaged for each ring. To measure the TRBF, 
the principle of Doppler effect is utilized where the frequency shift (∆f) from backscattered light 
is detected and simplified to: 
∆𝑓 =
−2𝑛𝑉𝑐𝑜𝑠𝛼
𝜆0
……………………………………………………………………………. (3.1) 
Where, V is the velocity of the moving particle, 𝜃 is the angle between the OCT beam and the 
flow, n is the refractive index of the medium, and 𝜆0 is the wavelength of the incident beam.  
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Flow in single vein=average (Vmax/Pi*Doppler phase shift*sin (Doppler angle))*vessel area, 
Vmax is the maximum speed corresponding to Doppler phase wrapping limit. Flow from 
individual retinal venules is then summed up to obtain the total volumetric blood flow at one 
time point.  
From the measured Doppler shift with in the vessel and Doppler angle estimation from the vessel 
center depth difference between two concentric rings, volumetric flow is derived using a semi-
automated software (version 2.1.1.4) algorithm named DOCTORC.
41,42
 The repeatability of 
TRBF measurements acquired using Doppler SD-OCT was reported in previous publications 
from our lab.
43,44
 
3.2.3.2 Hyperspectral Retinal Camera (HRC) 
The Hyperspectral Camera (Optina Diagnostics, Montreal, Canada) is a combination of a 
custom-built mydriatic fundus camera, a tunable light source, and a computer that controls image 
acquisition protocols, data storage and data analysis. The fundus is sequentially illuminated using 
monochromatic light of predetermined range of wavelengths. At each wavelength, a 30° field-of-
view of the posterior pole of the fundus is captured at high resolution (1.3 Megapixels). The 
filters are capable of delivering monochromatic light at a narrow bandwidth (FTMW = 2nm) and 
image acquisition occurs at a rate of 27 frames (wavelengths) per second. This allows the 
instrument to generate a stack of high resolution monochromatic fundus images (spectral data 
cube) within few seconds.   
A spectral data cube obtained by the HRC needs to be pre-processed before it can be analyzed. 
The spectral data cube is first normalized for spatial and spectral variations in light source 
intensity and any background ‘noise’ generated  from the system optics is removed.  Next, each 
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image of the data cube is spatially registered with the rest of the images in the stack to correct for 
any motion artifacts.
45
 A pre-processed data cube is then opened with an in-house Matlab (The 
Mathworks, Natick, MA) program.  An automatic vessel segmentation algorithm
46
 is then used 
to isolate the main vessel in the fundus image. The segmented vessel is further analyzed to 
determine the SO2 (Figure 3.1).  An inferior or superior temporal arteriole and venule is chosen 
for retinal blood SO2 measurements. An average of five SO2 values were obtained along the 
chosen vessel location close to the optic nerve head where the vessels are relatively large and 
therefore less impacted by relatively small registration errors. In this study, SO2 of a retinal 
blood vessel at half DD distance from the disc margin was compared at different PETO2 levels; 
images were captured between 500 and 650 nm in 5 nm steps for each stage of gas provocation. 
 
Figure 3.1 Oxygen saturation map of retinal vessels (Scale 0% -100%). Some of the vessels show 
implausible changes in retinal blood SO2 along their course. These artifacts are secondary to 
imperfections in image registration but, they have minimal effect on the calculation of blood SO2 because 
the measurements are acquired within 1DD of the optic nerve head where the vessels are relatively large 
and therefore impacted less by relatively small registration errors. The SO2 measurement site was in this 
case on the inferior temporal arteriole and temporal to the optic nerve head. 
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3.2.3.3 Gas delivery system 
A sequential rebreathing circuit (Hi-Ox
80
, Viasys Healthcare, Yorba Linda, CA) was used to 
provoke isocapnic hyperoxia and hypoxia. It comprises a fresh gas reservoir and an expiratory 
gas reservoir. Each reservoir is connected to a face mask with separate one-way valves. The face 
mask covers the mouth and nose of the subject. In turn, the two reservoirs are inter-connected 
using a positive end-expiratory pressure valve which allows subjects to breathe exhaled gas (i.e. 
rebreathe CO2-enriched gas) when the fresh gas reservoir is depleted.
39,40 The subject’s minute 
CO2 production and O2 consumption, gas flow and composition entering the SGD breathing 
circuit was attained using an automated gas flow controller (RespirAct
TM
, Thornhill Research, 
Inc., Toronto, Canada) which is connected to a computer. The RespirAct has been described in 
detail in previous publications.
12,25 
3.2.4 Procedures 
The study is performed over two visits. At the first visit, logMAR visual acuity and intra ocular 
pressure (using the Goldmann Applanation Tonometer; Haag-Streit, Koniz, Switzerland) was 
recorded for both eyes. However, one eye was randomly selected for the study and dilated with 
one drop of tropicamide 1.0% ophthalmic solution (Alcon, Mississauga, Canada). Following that 
a 10 minute resting time was given to the participants in a sitting position under room 
temperature in order to stabilize cardiovascular parameters. Participants were fitted with a face 
mask connected distally to the RespirAct
TM
 face mask and sequential re-breathing circuit gas 
delivery system. At the end of this stabilization period, resting blood pressure, peripheral 
capillary oxygen saturation (SpO2), retinal blood SO2, and TRBF measurements was taken during 
normoxia, hyperoxia and hypoxia using the HRC and the Doppler SD-OCT, respectively.  
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The order of hyperoxia and hypoxia was randomized between subjects. Pulse rate, SPO2 and 
blood pressure was monitored continuously using a rapid response critical care gas analyzer 
(Cardiocap 5; Datex-Ohmeda, Helsinki, Finland) and transmitted electronically to a data 
acquisition system (S5 Collect, Datex-Ohmeda, USA). A period of 10-12 minute was given in 
between the gas provocation challenges. Visit 2 was conducted on the same participants, one 
week after the first visit, except that the order of provocation was altered this time. A 
diagrammatic representation of study protocol is illustrated in figure 3.2. 
 
Figure 3.2 The figure demonstrates two different gas provocation protocols utilized for visits 1 and 2 
under various PETO2 levels (300 to 50 mmHg). Protocol 1 (left): Isocapnic hypoxia (A, B & C) followed 
by isocapnic hyperoxia (D & E). Protocol 2 (right): Isocapnic hyperoxia (A & B) followed by isocapnic 
hypoxia (C, D & E). The order of provocation was randomized between subjects. BL-baseline, PETO2 - 
end-tidal partial pressure of oxygen, PETCO2 - end-tidal partial pressure of carbon dioxide. 
3.2.5 Statistical analysis 
The normality of the data was ensured using Shapiro-Wilk test. The significant change in TRBF 
(µL/min) and SaO2 (%) and SvO2 (%) during various gas provocation stages were analyzed 
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using a repeated measures analysis of variance (reANOVA). If a significant result was achieved 
using reANOVA, then post hoc testing was performed using Tukey’s honestly significant 
difference (HSD) test. The coefficient of repeatability (COR) and coefficient of variability 
(COV) between visits was calculated as COR: 1.96*SD of difference; COV (%): SD/Mean*100.  
Bland & Altman plots illustrating repeatability of measurements between visits were plotted. For 
correlation analysis, Pearson’s correlation coefficient (r) was used. An “r” can be any value 
between +1 to -1. A value greater than 0 indicates a positive association between the variables, 
whereas, value less than 0 indicate negative association. Statistica software (StatSoft, Inc., Tulsa, 
OK, USA) version 12.0 was used for analyzing the data. The level of significance was set to be 
p<0.05.  
3.3 Results 
Eleven healthy subjects underwent retinal hemodynamic and retinal blood SO2 measurements 
under conditions of normoxia, isocapnic hypoxia and isocapnic hyperoxia. The participant’s 
mean age was 33.36 yrs (+ 6.03). For the repeatability analysis, TRBF measurements from 11 
subjects was included, however, for SaO2 measurements, data of ten subjects was included, 
except one, due to poor image quality.  
Systemic hemodynamic parameters for all participants across two visits are shown in tables 3.1 
and 3.2. Retinal hemodynamic parameters studied are given in table 3.3. During both visits, the 
differences in heart rate (HR) and SpO2 at various PETO2 levels, reached statistical significance 
(p<0.05). Diastolic blood pressure only showed a significant change (p=0.007) during the first 
visit. PETCO2 and systolic blood pressure were not different at the two study days. 
Inter-visit repeatability and variability of TRBF/retinal blood SO2  
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The Inter-visit repeatability of TRBF and SO2 measurements were analysed and plotted using the 
Bland and Altman method as shown in figure 3.3. The overall COR for TRBF, SaO2 (arteriolar 
blood SO2) and SvO2 (venular blood SO2) measurements was 21.8 µL/min, 18.4%, and 15.2%, 
respectively. The overall COV for TRBF, SaO2 and SvO2 measurements was 15.1%, 4.7% and 
6.9%, respectively (Tables 3.4 &3.5). 
 
Figure 3.3 Bland and Altman plots showing difference in measurements as a function of average TRBF 
(left) and average SaO2 (right) across the two visits. The dotted lines represent the limits of agreement and 
the center bar represents the mean of the differences between visits. 
 
TRBF response to changes in PETO2 
TRBF measurements during changes in PETO2 are shown in figure 3.4. There was no significant 
difference in baseline TRBF measurements as compared between visits. The average TRBF was 
44.60 + 8.9 µL/min during visit1. When the arterial PETO2 was increased from baseline 
(PETO2=100mmHg) to 200 and 300mmHg, the TRBF significantly reduced (reANOVA, p=0.020) 
from 44.60 μL/min (+8.9) to 40.28 μL/min (+8.9) and 36.23 μL/min (+4.6), respectively. 
Conversely, lowering the arterial PETO2, from baseline to 80, 60 and 50mmHg, increased the 
TRBF significantly (reANOVA, p=0.04) from 43.17 μL/min (+12.7) to 45.19 μL/min (+5.5), 
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49.71 μL/min (+13.4) and 52.89 μL/min (+10.9), respectively. A post-hoc analysis for pairwise 
comparison was performed using Tukey’s HSD test. The results show that the changes in TRBF 
was statistically significant only during baseline vs 300mmHg hyperoxia (p=0.010) and baseline 
vs 50mmHg hypoxia (p=0.040). 
 
Figure 3.4 Box plots represent change in TRBF at various PETO2 levels. The legend in the middle of the 
box represent the median value, the upper and lower extremes of the box represent 25th and 75th 
percentiles, the error bars represent the nonoutlier range and circle represent outliers. *p<0.05; **p<0.01. 
 
SaO2 and SvO2 response during PETO2 changes 
Retinal blood SaO2 and SvO2 measurements during stable change in PETO2 levels are shown in 
figure 3.5. Lowering the arterial PETO2 from baseline (100mmHg) to 80, 60 and 50mmHg, 
reduced the retinal arterial and venous blood SO2 content from 99.3 % (+ 5.8) and 56.3% (+ 4.2) 
to 95.6% (+ 5.1) and 52.5 (+ 4.1), 89.6% (+ 2.8) and 49.5% (+ 2.9), 83.3% (+ 3.9) and 45.0 % (+ 
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6.1), respectively (reANOVA, p=0.00). A Tukey’s HSD test revealed a significant difference in 
SaO2 and SvO2 during baseline vs 80mmHg (p=0.018, p=0.013) baseline vs 60mmHg (p=0.000, 
p=0.000) and baseline vs 50mmHg (p=0.000, p=0.000). SvO2 was significantly different during 
baseline vs 200mmHg (p=0.018) and baseline vs 300mmHg (p=0.006). However, no significant 
change in retinal blood SaO2 occurred at 200 and 300mmHg; compared to baseline. 
 
Figure 3.5 Error bars showing group mean retinal arteriolar blood SO2 (left) and venular blood SO2 
(right) at various PETO2 levels. *p<0.05; **p<0.01; ***p<0.001. 
 
Correlation analysis of TRBF and SO2 
The relationship between dependent variables such as TRBF, venous area, SaO2, and SvO2, 
during changes in PETO2 was illustrated as scatterplots in figure 3.6. The correlation analysis 
shows how the variables studied are associated with each other. For example, an increase in 
TRBF due to reduced PETO2, decreases the retinal blood SaO2 (Figure 3.6A); and SvO2 (Figure 
3.6B). The venous area changes, i.e. vasoconstriction during hyperoxia and vasodilation during 
hypoxia, were positively correlated with a decrease and increase in TRBF, respectively (Figure 
3.6C). Using the Pearson correlation coefficient, a statistically significant relationship was found 
between TRBF and SaO2 (r= -0.4, p<0.05) as well as TRBF and SvO2 (r= -0.37, p<0.05) (Figure 
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3.6A & 3.6B). Also, the correlation between retinal blood flow changes and simultaneous venous 
area changes during stable changes in PETO2 was r=0.5, p<0.05 (Figure 3.6C). 
 
Figure 3.6 Scatterplots of A) TRBF (µL/min) against SaO2 (%) B) TRBF (µL/min) against SvO2 (%) C) 
TRBF (µL/min) against venous area (x10
2
mm
2
) during all gas provocation stages; dotted lines indicate 
confidence limits; different plot legend indicates various PETO2 level. Squares, 300mmHg; hexagons, 
200mmHg; diamonds, 100 mmHg; triangles, 80 mmHg; circles, 60 mmHg; inverted triangles, 50 mmHg. 
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Table 3.1Group mean (+SD) for gas and cardiorespiratory parameters across various levels of PETO2 
during visit 1 (PETCO2-partial pressure of end-tidal carbon dioxide, SBP-systolic blood pressure, DBP-
diastolic blood pressure, HR-heart rate, bpm-beats per minute, PETO2-partial pressure of end-tidal oxygen, 
SPO2-peripheral capillary oxygen saturation). Note: NS denotes not significant; Level of significance was 
set to p<0.05. A significant p value represents change in a given parameter over the different provocations 
studied. 
  
Gas& Systemic 
Parameters 
(N=11) 
PETO2=300 
mmHg 
 
PETO2=200 
mmHg 
 
PETO2=100 
mmHg 
 
PETO2=80 
mmHg 
 
PETO2=60 
mmHg 
 
PETO2=50 
mmHg 
 
p value 
(reANOVA) 
 
Visit 1 RTVue 
PETCO2 
(mmHg) 
32.2 + 1.6 32.7 + 1.2 33.5 + 1.8 32.4 + 1.6 32.8 + 1.7 32.7 + 1.5 NS 
SBP (mmHg) 117.4 + 9.6 116.6 + 9.4 114.6 + 10.0 118.7 + 12.4 116.9 + 12.3 119.7 + 13.7 NS 
DBP (mmHg) 79.5 + 5.5 77.5 + 6.2 76.6 + 5.4 75.7 + 5.4 79.2 + 7.7 81.3 + 7.8 p=0.007 
HR (bpm) 71.3 + 8.6 73.2 + 6.8 75.1 + 4.2 75.5 + 8.6 77.0 + 7.2 78.7 + 11.3 p=0.019 
SpO2 (%) 99.6 + 0.3 99.3 + 0.4 98.2 + 0.8 96.8 + 1.7 89.9 + 4.1 83.9 + 2.9 p=0.000 
 
PETCO2 
(mmHg) 
32.8 + 2.0 33.0 + 1.5 33.8 + 2.5 32.9 + 1.3 33.1 + 1.6 32.8 + 1.3 NS 
SBP (mmHg) 118.3 + 11.8 119.1 + 12.2 116.8 + 11.3 118.3 + 11.3 116.9 + 15.3 118.5 + 14.7 NS 
DBP (mmHg) 79.0 + 7.6 78.7 + 9.6 75.7 + 9.7 80.6 + 8.9 78.5 + 9.7 77.4 + 10.9 NS 
HR (bpm) 73.4 + 9.6 74.3 + 10.3 78.4 + 10.3 78.1 + 9.4 79.4 + 8.9 82.0 + 9.3 p<0.001 
SpO2 (%) 99.6 + 0.5 99.4 + 0.4 98.1 + 0.7 95.2 + 2.0 87.5 + 1.8 84.0 + 5.4 p<0.000 
Visit 1 HRC 
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Table 3.2 Group mean (+SD) for gas and cardiorespiratory parameters across various levels of PETO2 
during visit 2 (PETCO2-partial pressure of end-tidal carbon dioxide, SBP-systolic blood pressure, DBP-
diastolic blood pressure, HR-heart rate, bpm-beats per minute, PETO2-partial pressure of end-tidal oxygen, 
SPO2-peripheral capillary oxygen saturation). Note: NS denotes not significant; Level of significance was 
set to p<0.05. 
  
Gas& Systemic 
Parameters 
(N=11) 
PETO2=300 
mmHg 
 
PETO2=200 
mmHg 
 
PETO2=100 
mmHg 
 
PETO2=80 
mmHg 
 
PETO2=60 
mmHg 
 
PETO2=50 
mmHg 
 
p value 
(reANOVA) 
 
Visit 2 RTVue 
PETCO2 
(mmHg) 
33.1 + 1.9 32.4 + 1.5 33.3 + 1.76 33.0 + 1.5 33.4 + 1.8 32.8 + 1.5 NS 
SBP (mmHg) 117.8 + 7.6 114.0 + 9.6 116.5 + 8.8 114.0 + 8.2 115.4 + 7.5 115.2 + 9.7 NS 
DBP (mmHg) 77.3 + 4.9 76.1 + 6.3 75.3 + 4.3 76.5 + 5.1 77.4 + 6.6 74.6 + 6.2 NS 
HR (bpm) 68.4 + 5.6 72.9 + 7.2 71.9 + 7.2 79.9 + 9.9 77.6 + 7.3 81.8 + 10.2 p=0.000 
SpO2 (%) 99.6 + 0.4 99.3 + 0.3 98.7 + 0.8 96.2 + 1.3 89.9 + 2.4 84.6 + 6.1 p=0.000 
        
Visit 2 HRC 
PETCO2 
(mmHg) 
32.6 + 1.4 32.7 + 1.5 33.1 + 1.6 33.3 + 1.6 33.1 + 1.7 33.0 + 1.6 NS 
SBP (mmHg) 116.7 + 9.1 114.3 + 9.6 116.0 + 11.3 113.6 + 10.3 114.6 + 12.1 113.8 + 10.2 NS 
DBP (mmHg) 73.8 + 7.8 76.2 + 6.7 75.2 + 7.6 73.0 + 7.5 73.5 + 4.7 76.3 + 7.7 NS 
HR (bpm) 71.6 + 6.4 74.0 + 7.7 79.1 + 8.0 76.0 + 5.5 76.6 + 6.4 80.1 + 4.6 p=0.000 
SpO2 (%) 99.4 + 0.4 99.3 + 0.5 98.1 + 1.0 95.9 + 2.0 89.6 + 3.4 82.6 + 1.7 p=0.000 
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Table 3.3 Group mean (+SD) for retinal hemodynamic parameters across various levels of PETO2 during 
visits 1 and 2 (PETO2-partial pressure of end-tidal oxygen, TRBF-total retinal blood flow, SaO2-arteriolar 
blood oxygen saturation, SvO2-venular blood oxygen saturation). Note: NS denotes not significant. 
*p<0.05; **p<0.01; ***p<0.001vs baseline (PETO2=100 mmHg). 
  
Retinal 
Parameters 
(N=11) 
PETO2=300 
mmHg 
 
PETO2=200 
mmHg 
 
PETO2=100 
mmHg 
 
PETO2=80 
mmHg 
 
PETO2=60 
mmHg 
 
PETO2=50 
mmHg 
 
p value 
(reANOVA) 
 
Visit1 
TRBF 
(µL/min) 
36.23 (4.6)* 40.28 (8.9) 43.59 (9.2) 45.19 (5.5) 49.71 (13.3) 52.89 (10.9)* p<0.000 
Venous area 
(×102mm2) 
4.91 (0.6) 4.98 (0.8) 5.38 (1.1) 5.52 (0.8) 6.00 (1.3) 6.38 (0.6)* p<0.000 
Venous 
velocity 
(mm/s) 
11.54 (1.6) 12.32 (2.2) 13.46 (2.7) 14.4 (1.8) 13.7 (3.3)  13.4 (3.6) p=0.040 
SaO2 (%) 106.6 (9.0) 103.4 (7.7) 101.9 (6.3) 95.6 (5.1)* 89.6 (2.8)*** 83.3 (3.9)*** p<0.000 
SvO2 (%) 62.0 (3.4)** 61.3 (3.6)* 
 
57.2 (3.9) 
 
52.5 (4.1)* 49.5 (2.9)*** 45.0 (6.1)*** p<0.000 
Visit 2 
TRBF 
(µL/min) 
 
38.9 (10.0) 
 
42.26 (8.2) 
 
44.72 (12.8) 
 
49.77 (9.7) 
 
51.12 (10.3) 
 
52.28 (17.7) 
 
p<0.001 
Venous area 
(×102mm2) 
 
4.91 (0.6) 
 
5.02 (0.9) 
 
5.36 (0.8) 
 
5.52 (0.8) 
 
6.04 (1.3) 
 
6.34 (0.5)** 
 
p<0.001 
Venous 
velocity 
(mm/s) 
 
14.31 (3.1) 
 
14.12 (2.3) 
 
13.8 (2.4) 
 
13.18 (1.3) 
 
14.39 (3.0) 
 
13.11 (2.1) 
 
NS 
SaO2 (%) 
(n=10) 
 
113.3 (13.0) 
 
106.8 (7.7) 
 
104.4 (7.8) 
 
 
96.4 (4.5)* 
 
91.3 (2.7)*** 
 
84.2 (4.6)*** 
 
p<0.001 
SvO2 (%) 
(n=10) 
 
68.0 (7.2)* 
 
66.8 (4.8)* 
 
60.3 (6.8) 
 
 
53.8 (5.6)* 
 
54.6 (6.3) 
 
46.7 (6.3)*** 
 
p<0.001 
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Parameters 
(N=11) 
Visit 1 
Mean + SD 
Visit 2 
Mean + SD 
COR COV (%) ANOVA 
TRBF 
(µL/min) 
43.59 + 9.2 
 
44.72 + 12.8 
 
 
21.8 
 
 
15.1 
 
 
NS 
 
Venous area 
(×10
2
mm
2
) 
5.31 + 1.1 5.36 + 0.8 20.0 11.2 
 
NS 
 
Venous velocity 
(mm/s) 
13.46 + 2.7 13.8 + 2.4 6.19 12.3 NS 
SaO2 (%) 101.9 + 6.3 
 
104.4 + 7.8 
 
 
18.4 
 
 
4.7 
 
 
NS 
 
SvO2 (%) 
 
57.2 + 3.9 
 
 
60.3 + 6.8 
 
 
15.2 
 
 
6.9 
 
 
NS 
 
Table 3.4 Baseline comparison of mean, standard deviation (SD) of blood flow and retinal blood SO2 
parameters between visits (COV-coefficient of variability, COR-coefficient of repeatability, SaO2-
arteriolar blood oxygen saturation, SvO2-venular blood oxygen saturation, NS-not significant). 
COR=1.96* SD of differences; COV (%) = SD/Mean. 
  60 
PETO2 
(mmHg) 
300 200 
 
100 80 60 50 
COR COV 
(%) 
COR COV 
(%) 
COR COV 
(%) 
COR COV 
(%) 
COR COV 
(%) 
COR COV 
(%) 
 
TRBF 
(µL/min) 
 
20.5 
 
16.5 
 
21.7 
 
15.3 
 
21.8 
 
 
15.1 
 
 
19.6 
 
13.5 
 
21.5 
 
11.9 
 
31.2 
 
17.7 
 
SaO2 
(%) 
 
20.0 
 
6.0 
 
23.2 
 
6.8 
 
18.4 
 
 
4.7 
 
 
13.7 
 
3.4 
 
7.7 
 
2.5 
 
10.4 
 
3.4 
 
SvO2 
(%) 
 
13.0 
 
7.8 
 
10.8 
 
7.5 
 
15.2 
 
 
6.9 
 
 
11.2 
 
5.8 
 
14.2 
 
8.6 
 
12.7 
 
9.0 
Table 3.5 COR and COV for TRBF and retinal blood SO2 for all PETO2 stages between visits (COV-
coefficient of variability, COR-coefficient of repeatability, SaO2-arteriolar blood oxygen saturation, 
SvO2-venular blood oxygen saturation, TRBF-total retinal blood flow). COR=1.96* SD of differences; 
COV (%) = SD/Mean. 
 
3.4 Discussion 
The current study showed that the RBF and retinal blood SO2 measurements acquired using two 
novel prototype instruments; the Doppler SD-OCT and the HRC, during changes in arterial O2 
tension are repeatable and consistent. The previous methods to quantitate RBF, such as the 
CLBF and LDV are all limited to quantitating blood flow from one vessel at a time.
34,47
 
Techniques like fluorescein angiography are invasive and have few associated side effects due to 
dye injection.
24,48
 Ultrasound based color Doppler imaging only determines the blood flow 
velocity, however, RBF quantification is not possible due to the lack of vessel diameter 
measurement.
48,49
 Overcoming the limitations of the above mentioned techniques, the Doppler 
SD-OCT could achieve TRBF from all major arterioles and venules. In this study, alongside the 
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TRBF measurements, retinal arteriolar and venular blood SO2 was also achieved using the HRC. 
Recently, Palkovits and co-workers
21,69
 have reported retinal blood SO2 and RBF during hypoxia
 
 
and hyperoxia in humans. RBF increased while retinal blood SO2 decreased during two levels of 
hypoxia studied.
21
 During hyperoxia, a significant decrease in RBF, vessel diameter and velocity 
observed as well as SO2 increased in retinal arteries and veins by +4.4% and + 19.6%, 
respectively.
69
 One needs to note that, in their studies, RBF measurements were achieved from 
one single vein as compared to TRBF reported in current study. Also, the vessel diameter and 
blood flow measurements were acquired using two different instruments, unlike simultaneous 
acquisition using Doppler SD-OCT. 
The combination of computer-controlled gas sequencer along with the RBF and SO2 
measurements, allows the precise combinations of PETO2, while clamping the PETCO2 (i.e. to be 
able to achieve isocapnic hyperoxia and isocapnic hypoxia) concentrations, in turn this provides 
more reliable and reproducible data. The gas parameters were highly reproducible. 
Studies quantitating both RBF and retinal blood SO2 in humans are very few in literature. Most 
of the experiments have equipped microspheres to provide direct measurements of inner retinal 
O2 tension and O2 consumption in animals. Such techniques are more invasive and less than ideal 
to be used in humans.
22,50
 The current study validates two novel prototype instruments to 
measure RBF and SO2 non-invasively in young healthy individuals. Validation of these 
techniques might facilitate further understanding of retinal O2 extraction in normal as well as in 
diseased eyes.  
Our lab has previously reported a COR of 11% and 14% for SaO2 and SvO2, respectively, using 
hyperspectral retinal camera in six healthy subjects.
45
 The current study documents COR of 
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18.4% and 15% for SaO2 and SvO2, respectively, using HRC. It is interesting to note that, the 
COR for SvO2 is similar to what the previous author has reported, however, the COR of SaO2 
has a greater difference compared to the previous study. It is unclear whether this could be due to 
larger variability in SaO2 measurements among individuals. In our study itself, we noticed few 
subjects had SaO2 values beyond 100% during baseline conditions (i.e. normoxia), which is 
beyond the physiological range reported in literature.
51,52
 Similar results were also published 
previously by many authors. Mordant and co-workers
53
 reported mean SaO2 of 104.3 % 
(+16.7%) in retinal arterioles using a ‘snapshot’ hyperspectral spectral imaging technique. 
Hardarson and co-workers
54
 achieved SaO2 values ranging between 93%-108% by using 
automated image analysis software to derive optical density ratios of arterioles.  
In contrast to flash or snap-shot hyperspectral retinal cameras, the HRC constructs a spectral data 
cube based on sequential imaging (non-flash). There is evidence to suggest that using flash 
illumination may artificially alter the measured retinal SO2 values.
55 
On the other hand, 
sequential imaging is more susceptible to motion artifact, however, HRC’s high frames per 
second imaging capability helps to minimize this effect. 
Hammer and co-workers
56
 reported average SaO2 and SvO2 of 98% + 10.1% and 65% + 11.7 %, 
respectively under normoxia. During 100% O2 breathing the arterial and venous SO2 increased 
by 2% and 7% respectively. Hardarson and co-workers
57
 have shown that the SaO2 increased 
from 96% (+ 9%) to 101% (+ 8%) during hyperoxia.  In our study, the SaO2 and SvO2 during 
normoxia was 99.3% (+5.8%) and 56.3% (+4.2%). During hyperoxia (PETO2=300mmHg), the 
retinal SaO2 and SvO2 increased by 4.7% and 4.8%, respectively. In contrast, during hypoxia 
(PETO2=50mmHg) we found a reduction in SaO2 and SvO2 values to 16% and 11.3% compared 
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to baseline. The variability of SO2 measurements reported in our study is much less compared to 
those reported by similar studies in literature. Figure 3.5 shows almost a “linear” trend of SaO2 
and SvO2 in response to decrease in PETO2 below 100mmHg. This trend suggests a positive 
relationship between the systemic changes in PETO2 to that of the changes in retinal blood SO2. 
Garhofer and Co-workers
34
 have reported a high inter-individual variability in TRBF (44.0 + 
13.3 μL/min) measurements using bidirectional LDV, in young healthy subjects. One needs to 
note here that TRBF reported is not from the simultaneous measurement of retinal blood velocity 
and vessel diameter, rather it is derived from one vessel at a time due to the technological 
limitations.  In contrast to bi-directional LDV, Doppler SD-OCT utilizes “Doppler shift” 
principle to quantitate the red blood cell velocity from all major arterioles and venules in single 
point of time.
32
 Venous area measurements are extracted from the acquired Doppler OCT images 
using a semi-automated software named DOCTORC. Although there are manual steps involved 
in venous area estimation using DOCTORC, few studies have actually reported the repeatability 
and variability of the manual grading technique, per se.
41-43
 
A recent study from our lab have reported a COV of 7.5% and COR of 6.43 μL/min in young 
adults using Doppler SD-OCT.
44
 Wang and co-workers
32,33
 reported mean TRBF in healthy 
young subjects as 45.6 + 3.8 μL/min and COV of 10.5% using a single-beam FD-OCT. Our 
study report a TRBF of 43.59 + 9.2 μL/min, which is comparable to the previous studies. In our 
study, the reported COV and COR for TRBF during normoxia was 15.1% and 21.8 μL/min. 
During hyperoxia (PETO2=300mmHg) TRBF is decreased by 8.37 μL/min and during hypoxia 
(PETO2=50mmHg) TRBF increased by 9.72 μL/min compared to baseline. Due to the large 
variability in blood flow data (Figure 3.4), as well as smaller sample recruited, a significant 
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difference in TRBF was not achieved during rest of the PETO2 stages (i.e. PETO2 of 200,80,60 
mmHg).  
Hyperoxia is an increase in arterial partial pressure of oxygen from baseline homeostatic levels. 
Several studies have shown that retinal vessels react to hyperoxia by local constriction of 
arterioles, venules and to a lesser extent in capillaries; thereby reducing the RBF.
8,13,15
 Recently 
Palkovits and co-workers
70
 have reported the effect of breathing 100% oxygen on flicker-
induced vasodilation in humans. In contrast to animal studies,
71
 breathing oxygen was showed to 
increase the flicker induced retinal vasodilation in humans. In our study, we mainly emphasized 
on the physiological responses of retinal vasculature to hyperoxia alone without involving neuro-
vascular coupling.  
Studies from other labs have just used 100% O2 or coadministerd O2 (~>90%) and CO2 (~5%), 
without clamping the PCO2 for hyperoxic provocation.
8,10,16
  This might further reduce the PCO2 
concentration, which might impact the measured variables.
58
 The novel computer-controlled gas 
provocation technique used in the current study has overcome the above mentioned limitation by 
minimizing alterations to the systemic PCO2 concentration during both hyperoxic and hypoxic 
provocation, thereby streamlines the retinal vascular reactivity response to O2 only. It has been 
reported that endothelin-1 is known to mediate the vasoconstrictive response to hyperoxia.
59
 
However, animal studies have reported that, other factors such as thromboxane and 20-
hydroxyeicosatetraenic acid might as well contribute to hyperoxia-induced vasoconstriction.
60
 
This remains to be investigated in humans. 
Hypoxia leads to increase in blood flow, due to vasodilation.
21,22
 The current study utilized safe 
levels of hypoxia to study the TRBF and SO2 changes. In humans, lower ATP (adenosine 
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triphosphate) levels as well as release of the metabolite adenosine during hypoxia would lead to 
an increased retinal vessel diameter.
61
 Few animal studies have reported other metabolic factors 
such as retinal lactate,
62
 adenosine, retinal relaxing factor
63
 and nitric oxide
64
 to mediate retinal 
blood flow response to hypoxia.  
In this study, retinal blood SO2 is found to be significantly reduced during changes in arterial O2 
tension i.e. below 100mmHg; above which, there seems to be no significant change in retinal 
blood SaO2, since the hemoglobin is almost 100% saturated. The increase in blood flow during 
hypoxia as shown in the present study compensates for the reduced retinal blood SO2; thereby, 
demonstrating the regulation of inner retinal tissue during hypoxic environment. Our results 
demonstrate an inverse linear relationship between TRBF and retinal blood SO2 in response to 
hypoxia as shown in Figure 3.6A & 3.6B. This finding is consistent with other cerebral
65,66
 and 
retinal
21
 studies in literature.   
At the same time, decreased blood flow during hyperoxia is due to the vasoconstricting ability of 
retinal vessels. The higher concentration of O2 in retina leads to an increased retinal arteriolar 
and venular blood SO2. Also, the dissolved O2 from choroid might as well increase the O2 
concentration in the retina considerably.
67,68
  
There are possible limitations involved with this study. The TRBF derived using DOCTORC 
software needs several manual input in terms of grading, such as, defining the cross-sectional 
area for retinal vessels from the Doppler OCT image and assigning confidence score based on 
the Doppler signal. The Doppler signal achieved was not uniform among all the scans from the 
same subject under various PETO2 levels; this might have underestimated or overestimated the 
blood flow and vessel area estimation. Due to the long study duration (~3 hours), subject’s lack 
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of concentration to fixate and eye movements, image registration limitations using a manual 
system might have possibly influenced the quality of scans obtained or the quality of the 
acquired data. In Figure 3.1, the implausible changes in saturation along some of the vessels are 
due to artifact secondary to imperfections in image registration. This possibly could have 
attributed to the variability in the results. Keeping in mind that, the image acquisition and image 
analysis was performed by trained personnel, the influence of human error could be considered 
minimal. It is very difficult to conceive how the operator might bias the result given that semi-
automated software is needed to translate the images into quantitative data. Retinal SO2 was 
measured in a single superior or inferior temporal retinal arteriole and venule close to the optic 
nerve head. This approach, rather than measuring total retinal SO2, was undertaken for a number 
of reasons: 1). There is a known marked regional variation in retinal SO2 between the 
hemifields
72
 2). The use of summary statistics to describe “total” retinal SO2 values will result in 
the loss of the technique to identify localized change. This study is first to report the TRBF and 
retinal blood SO2 measurements simultaneously in healthy subjects under conditions of hypoxia 
and hyperoxia. 
In conclusion, Doppler SD-OCT and HRC could provide reliable and reproducible TRBF and 
retinal blood SO2 measurements, respectively. By using a novel gas provocation technique to 
manipulate safe levels of PETO2, we have demonstrated that both the techniques could detect 
changes and showed the anticipated physiological response. In other words, increase in arterial 
PETO2 from baseline decreases the TRBF. Conversely, decreasing the arterial PETO2 from 
baseline increases the TRBF with simultaneous reduction in the retinal blood SO2. Retinal blood 
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flow and SO2 measurements performed under safe levels of hypoxia and hyperoxia were 
repeatable in healthy adults.  
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 Inner Retinal Oxygen Delivery and Consumption during Chapter 4
Hypoxia and Hyperoxia in Humans 
4.1 Introduction 
The retina has highest metabolic demand compared to any other tissue in the human body
1
 and is 
perfused by a vascular system with no or little redundancy, thus requiring an uninterrupted blood 
supply to stay healthy and to preserve vision. The retina has dual blood supply, namely, the 
retinal and the choroidal vasculature. The inner two-thirds of retina are supplied by the central 
retinal artery, whose major arteriolar branches are located in the nerve fiber layer. The outer one-
third of the retina is supplied by the choroidal vessels. The retinal vasculature has a low flow and 
higher O2 extraction (35-40%) compared to the choroidal system.
2
 Due to its higher flow, the 
choroidal vessels deliver approximately 60-80% of O2 consumed by the retina.
3
  
Studies investigating inner retinal O2 metabolism are receiving increased attention due to the 
relevance in understanding the pathophysiology of retinal diseases. Several studies have reported 
tissue hypoxia as a precursor for major retinal vascular diseases such as diabetic retinopathy,
4
 
AMD,
5,6
 and glaucoma.
7,8
  
To date, direct measurement of O2 delivery and consumption is restricted to animal studies due 
to the use of invasive techniques. In animals such as rat,
9,10 
pig,
3
 cat,
11
and rabbit,
12
 O2 sensitive 
microelectrodes are inserted into the eye to measure the O2 tension profile within retinal layers in 
order to derive the actual O2 consumption rate of the retina. However, very few studies have 
calculated the inner retinal O2 extraction in humans non-invasively.
13
   
The current study reports inner retinal oxygen delivery (DO2) and consumption (VO2) in young 
adults. Also, the ratio of tissue oxygen supply versus demand i.e. oxygen extraction fraction 
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(OEF) is calculated using Fick’s principle. Several cerebral studies indicate that increased OEF is 
associated with risk of cerebrovascular diseases.
14-17
 The mention of cerebral studies is due to the 
reduced availability of retinal studies in literature reporting OEF in humans, as well as due to the 
structural and physiological similarities of the two organs.
18,19
 As far as we are aware, the current 
study is the first to report normative data for the non-invasive estimation of inner retinal OEF in 
healthy individuals. However, Wanek and Co-workers have previously reported the inner retinal 
OEF in rats to be 0.46 under normoxia, which significantly increased to 0.67 during hypoxia. 
4.2 Materials and methods 
4.2.1 Subjects 
This study was approved by the University of Waterloo Office of Research Ethics, Waterloo, and 
by the University Health Network Research Ethics Board, Toronto; all the methods were carried 
out in accordance with the approved guidelines of these two research ethics organizations. One 
eye of 11 healthy subjects, mean age 33.36 yrs, SD 6.03 yrs was recruited. All subjects had a 
logMAR visual acuity of 0.0, or better. All participants were young, healthy and non-smokers. 
Exclusion criteria included any refractive error > + 6.00 Diopters sphere and / or + 1.50 Diopters 
cylinder, intra ocular pressure > 21mm Hg, treatable respiratory disorders (e.g. asthma), systemic 
hypertension, cardiovascular disease, diabetes, endocrine disorders, medications with known 
effects on blood flow (e.g. anti-hypertensive, medications with activity at autonomic receptors, 
smooth muscles, or those affecting nitric oxide release), family history of glaucoma, or a history 
of any ocular disease. All the participants were asked to abstain from caffeine, red meat and 
alcohol for 12 hours and avoid rigorous exercise about 1 hour prior to their study visit. Informed 
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consent was obtained from each subject after a thorough explanation of the nature of the study 
and its possible consequences, according to the tenets of the Declaration of Helsinki. 
4.2.2 Instrumentation 
4.2.2.1 Total Retinal Blood Flow (TRBF) measurement 
The novel prototype Doppler SD-OCT utilizes the principle of “Doppler effect” to non-
invasively quantitate the TRBF. The commercially available Optovue RTVue OCT (Optovue, 
Inc., Fremont, CA, USA), is a spectrometer-based OCT system, consist of a super luminescent 
diode with a center wavelength of 841 nm and a bandwidth of 49 nm. The axial resolution is 5.6 
µm in tissue and transverse resolution is 20 µm. The scan protocol for TRBF measurement 
consist of double circular Doppler scans in the form of two concentric rings of diameters 3.40 
mm and 3.75 mm centered on the optic nerve head, transecting all branch retinal arterioles and 
venules.
20
 A total of six scans were obtained and averaged for each ring. From the measured 
Doppler shift with in the vessel and Doppler angle estimation from the vessel center depth 
difference between two concentric rings, volumetric flow is derived using a semi-automated 
software (version 2.1.1.4) algorithm named DOCTORC.
21,22
 The repeatability of TRBF 
measurements acquired using Doppler SD-OCT was reported in previous publications from our 
lab.
23-25
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4.2.2.2 Retinal blood SO2 measurement 
In this study, retinal blood SaO2 and SvO2 measurements were achieved using the HRC. The 
HRC (Optina Diagnostics, Montreal, Canada) is a combination of a custom-built mydriatic 
fundus camera, a tunable light source, and a computer that controls image acquisition protocols, 
data storage and data analysis. The fundus is sequentially illuminated using monochromatic light 
of predetermined range of wavelengths. At each wavelength, a 30° field-of-view of the posterior 
pole of the fundus is captured at high resolution (1.3 Megapixels). The filters are capable of 
delivering monochromatic light at a narrow bandwidth (FTMW = 2nm) and image acquisition 
occurs at a rate of 27 frames (wavelengths) per second. This allows the instrument to generate a 
stack of high resolution monochromatic fundus images (spectral data cube) within a few seconds.   
A spectral data cube obtained by the HRC was pre-processed prior to analysis. The spectral data 
cube was first normalized for spatial and spectral variations in light source intensity and any 
background ‘noise’ generated from the system optics was removed. Next, each image of the data 
cube was spatially registered with other images in the stack to correct for any motion artifacts.
26
 
A pre-processed data cube was then opened with an in-house Matlab (The Mathworks, Natick, 
MA) code. An automatic vessel segmentation algorithm
 27
 was then used to isolate the chosen 
vessel in the fundus image. The segmented vessel was further analyzed to determine the SO2.  
4.2.2.3 Gas provocation technique 
A sequential rebreathing circuit (Hi-Ox
80
, Viasys Healthcare, Yorba Linda, CA) was used to 
provoke isocapnic hyperoxia and hypoxia. It comprises a fresh gas reservoir and an expiratory 
gas reservoir. Each reservoir is connected to a face mask with separate one-way valves. The face 
mask covers the mouth and nose of the subject. In turn, the two reservoirs are inter-connected 
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using a PEEP valve which allows subjects to breathe exhaled gas (i.e. rebreathe CO2-enriched 
gas) when the fresh gas reservoir is depleted.
28,29 The subject’s minute CO2 production and O2 
consumption, gas flow and composition entering the sequential breathing circuit was attained 
using an automated gas flow controller (RespirAct
TM
, Thornhill Research, Inc., Toronto, Canada) 
which is connected to a computer.
7,30 
4.2.3 Experimental Protocol 
The study was performed in a single visit. LogMAR visual acuity and intra ocular pressure 
(using the Goldmann Applanation Tonometer; Haag-Streit, Koniz, Switzerland) was recorded for 
both eyes. One eye was randomly selected for the study and dilated with one drop of tropicamide 
1.0% ophthalmic solution (Alcon, Mississauga, Canada). Following that a 10 minute resting 
time, or longer if necessary, was given to the participants in a sitting position under room 
temperature in order to stabilize cardiovascular parameters. Participants were fitted with a face 
mask connected distally to the RespirAct
TM
 face mask and sequential re-breathing circuit gas 
delivery system. At the end of this stabilization period, resting blood pressure, SpO2, retinal 
blood SO2, and TRBF measurements was taken during normoxia, hyperoxia and hypoxia using 
the HRC and the Doppler SD-OCT, respectively. Pulse rate, SPO2 and blood pressure was 
monitored continuously using a rapid response critical care gas analyzer (Cardiocap 5; Datex-
Ohmeda, Helsinki, Finland) and transmitted electronically to a data acquisition system (S5 
Collect, Datex-Ohmeda, USA). A period of 10-12 minute was given in between the gas 
provocation challenges. The order of hypoxia and hyperoxia as well as order of TRBF and SO2 
measurement was randomized between subjects (Figure 4.1). 
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Figure 4.1 Schematic representation of the study protocol. A and B represents the two gas provocation 
protocols i.e. A, Hyperoxia and Hypoxia B, Hypoxia and Hyperoxia. The order of hypoxia and hyperoxia 
was randomized between the subjects. (Note: the PETO2 scales are not linear). 
4.2.4 Calculation of retinal oxygen extraction 
Inner retinal O2 delivery: DO2 is the product of TRBF and the oxygen content of the arterial 
blood (CaO2) and is expressed in nL/min. 
DO2 = TRBF * CaO2………………………………………………………………….. (4.1)  
Inner retinal O2 consumption: VO2 is the product of TRBF and retinal blood arteriovenous 
difference in oxygen content (CaO2 - CvO2); where CaO2 is the oxygen content of the arterial 
blood and CvO2 is the oxygen content of the venous blood.  
VO2 = TRBF * (CaO2 - CvO2)…………………………………………………………… (4.2) 
This method of calculating oxygen consumption relies on the Fick’s principle which is based on 
the conservation of mass. In the above equation CaO2 is calculated as follows, 
CaO2 = SaO2*[Hb]*1.34 ml O2/gm Hb + 0.003ml O2/ (dL blood×mmHg)*PaO2………. (4.3) 
Where SaO2 is the oxygen saturation of the retinal arterial blood, Hb is the hemoglobin 
concentration and PaO2 is the arterial partial pressure of oxygen. In this study, end-tidal partial 
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pressure of oxygen (PETO2) measured using the sequential gas delivery system, was used as a 
surrogate for PaO2. Also, hemoglobin concentration was not measured, instead considered to be 
an average of 15gm/dL.
31
 To measure venous oxygen content the following equation was used, 
CvO2 = SvO2*[Hb]*1.34 ml O2/gm Hb + 0.003ml O2/ (dL blood×mmHg)*PvO2……… (4.4) 
Where SvO2 is the oxygen saturation of the retinal venular blood and PvO2 is venous oxygen 
partial pressure. Since PvO2 was not directly measured in the current study, the Hill equation and 
oxygen hemoglobin dissociation curve
32
 was used to estimate PvO2 from SvO2 measurement. 
The Hill equation is written as follows, 
𝑆𝑂2 =  
𝐾∗𝑃𝑂2
𝑛
1+𝐾∗ 𝑃𝑂2
𝑛………………………………………………………………………… (4.5) 
Oxygen Extraction Fraction (OEF): OEF was calculated from the ratio of VO2 to DO2 based on 
Fick’s principle,33   
𝑂𝐸𝐹 =
𝑉𝑂2
𝐷𝑂2
……………………………………………………………………………… (4.6) 
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4.2.5 Statistical analysis 
A repeated measures ANOVA was used to analyze the significant changes in retinal blood flow, 
retinal blood SO2, DO2, VO2 and OEF during hypoxia, hyperoxia and normoxia. If a significant 
result was achieved using reANOVA, then post-hoc testing was performed using Tukey’s HSD 
test. Data is presented as mean and SD. The level of significance was set to be p<0.05. For 
correlation analysis, Pearson’s correlation coefficient (r) was used. Statistica software (StatSoft, 
Inc., Tulsa, OK, USA) version 12.0 was used for analyzing the data.   
4.3 Results 
Systemic physiological parameters 
The systemic and gas parameters of the subjects during each breathing condition (i.e. normoxia, 
hyperoxia, and hypoxia) are given in table 4.1. PETO2 was significantly different between the 
breathing conditions (p=0.000). Heart rate and systemic peripheral oxygen saturation (SPO2) was 
significantly decreased during hypoxia (p<0.05). 
Inner retinal oxygen delivery, consumption and OEF 
Inner retinal DO2 and VO2 during normoxia was 8.48 mLO2/100g/min and 3.64 mLO2/100g/min, 
respectively. DO2 and VO2 during all the stages of gas provocation are shown in figure 4.2. OEF 
during normoxia was 0.43. There was no significant difference found in DO2, VO2 and OEF 
during hyperoxia or hypoxia compared to normoxia. Correlation between systemic arterial blood 
SO2 and retinal arteriolar blood SO2 was r=0.77 (p<0.05) (Figure 4.3) 
  
  76 
 
Figure 4.2 Mean DO2 (left) and VO2 (right) during hyperoxia and hypoxia. Box in the middle represents 
mean and vertical bars on either side denote 95% confidence intervals. 
 
 
Figure 4.3 Scatterplot of systemic arterial blood SO2 and retinal arteriolar blood SO2 during all gas 
provocation stages; dotted lines indicate confidence limits. 
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TRBF and SO2 during various PETO2 levels 
Hyperoxia (PETO2=300mmHg) 
During hyperoxia, TRBF decreased significantly (p=0.01) from 43.17 μL/min (+12.7) to 36.23 
μL/min (+4.6). SaO2 was not significantly different compared to baseline, however SvO2 showed 
a significant increase (p=0.005) compared to baseline.  
Hypoxia (Stage 1: PETO2=60mmHg; Stage 2: PETO2=50mmHg) 
Although there is a trend for increase of TRBF during stage 1 hypoxia (PETO2 = 60mmHg), the 
results were not statistically significant compared to baseline (PETO2 = 100mmHg). However, 
retinal blood SaO2 and SvO2 decreased significantly (p<0.050) from 101.9 % (+6.3) and 57.2 % 
(+3.9) to 89.6 % (+2.8) and 49.5 % (+2.9), respectively. TRBF significantly increased (p< 0.008) 
from 43.17 μL/min (+12.7) to 52.89 μL/min (+10.9) during stage 2 hypoxia (PETO2 = 50mmHg). 
Retinal blood SaO2 and SvO2 also reduced significantly (p<0.000) from 101.9 % (+6.3) and 57.2 
% (+3.9) to 83.3 % (3.9) and 45.0 % (+6.1), respectively. The percentage change in TRBF, 
retinal blood SaO2 and SvO2 during various PETO2 stages are shown in figures 4.4 and 4.5. 
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Figure 4.4 Bar graph shows percentage change from baseline in TRBF in response to hyperoxia 
(300mmHg) and hypoxia (60 and 50 mmHg). Level of significance was set to p<0.05. 
*p<0.001,**p<0.01. 
 
 
Figure 4.5 Bar graph shows percentage change from baseline in SaO2 and SvO2 in response to hyperoxia 
(300mmHg) and hypoxia (60 and 50 mmHg). Level of significance was set to p<0.05. **p<0.01, 
***p<0.05. 
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4.4 Discussion 
The current study estimates inner retinal convective O2 delivery and consumption in humans 
partly based on a number of assumptions. During the stages of hypoxia, both DO2 and VO2 seem 
to remain relatively constant compared to normoxia as shown in figure 4.2. For most participants 
there is a decreasing trend in both DO2 and VO2 during hyperoxia as compared to normoxia, but 
these changes are not statistically significant. Non-significant changes in VO2 and DO2 indicate 
that the hypoxic and hyperoxic values used are well within the regulatory range of the retinal 
vessels. Recently, Palkovits and Co-workers
34
 have also reported that, despite decrease in 
arteriovenous oxygen difference, the inner retinal oxygen extraction remains unaltered during 
two levels of graded hypoxia (12% O2 + 88% N2 and 15% O2 + 88% N2 breathing).  
The adequacy of oxygen supply relative to the metabolic demand of the tissue is given as OEF.
35
 
Previous animal studies utilized microelectrodes
36
 to measure retinal oxygen tension and 
consumption of the retina.
1,9,37  
In this study, calculations of oxygen tension in arterioles and 
venules were made from Fick’s principle which is based on the conservation of mass. Wanek and 
Co-workers
9
 have demonstrated that O2 delivery and consumption was maintained at a PaO2 of 
46mmHg relative to baseline but significantly decreases at 31mmHg PaO2 in rat. VO2 may 
become supply dependent at and below a PaO2 asymptote of ~37 mmHg where blood flow is 
maximum and unable to maintain oxygen delivery with reduced PaO2.
38
 The critical DO2 is 
likely near the PaO2 asymptote, below which delivery cannot meet demand and as a consequence 
OEF might begin to increase. 
Estimation of OEF has received significant attention in cerebral studies,
14,15,39
 but has not quite 
been investigated in the retina due to the lack of non-invasive techniques to quantify retinal OEF. 
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Cerebral imaging techniques may lack the resolution required to quantify retinal O2 extraction,
40
 
however, indirect estimation of the inner retinal OEF may be possible from retinal blood flow 
and blood oxygenation data. In the present study, RBF was measured using Doppler SD-OCT, 
and, retinal blood SO2 was quantitated using the HRC. These two data were utilized to calculate 
OEF using Fick’s principle. 
A few animal studies have calculated OEF of inner retina in rat under hypoxia
9 
as well as in 
response to light flicker.
41
 The reported OEF under normoxic conditions was 0.46, which is 
similar to our estimation of 0.43 in humans. During hypoxia, Wanek and Co-workers
9
 have 
reported a significant increase in OEF from 0.46 to 0.67. This trend was not observed in our 
study, due to relatively moderate level of hypoxia utilized. In diseases affecting the retinal 
metabolism, however, higher values of OEF might be expected in humans. This remains to be 
investigated in future studies. The significance of OEF has previously been reported in several 
cerebral studies, where higher OEF was considered a powerful predictor of cerebro-vascular 
diseases in humans.
17,42,43
  
It is interesting to note that, both DO2 and VO2 appear to show decreasing trends during 
physiological perturbations of hyperoxia as shown in figure 4.2. This decreased trend in DO2 is 
likely due to the overcompensation of the retinal arterioles during hyperoxia
36
 but is non-
significant because we used a lower hyperoxic stimulus as compared to previous studies which 
have generally used the inhalation of 100% O2.
34,44,46
 Caution must be used to interpret the trend 
that shows a decrease in VO2 during hyperoxia because retinal arterio-venous shunt may increase 
SvO2 causing an underestimation of VO2.  Furthermore, the contributions of the choroidal 
vasculature need to be taken into account because it may supply more oxygen to the inner retina 
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during hyperoxia due to the increase in the diffusive components of O2 delivery (i.e. increased 
partial pressure of O2). The choroid during hyperoxia may provide much of the O2 uptake of the 
inner retina, while the retinal vasculature provides less, leading to a lower calculated VO2 from 
Fick’s principle of material balances.  
The current study reports inner retinal DO2 of 8.48 mLO2/100g/min and respectively, in humans 
during normoxia. As a comparison, the inner retinal DO2 of 11.8 mLO2/100g/min
9
 was estimated 
in rat; a DO2 of 5.6 mLO2/100g/min was reported in newborn lamb.
45
 Similarly, inner retinal 
oxygen extraction i.e. VO2 reported in our study is 3.64 mLO2/100g/min, comparable to those 
found in other animals; 4.6 to 3.8 mLO2/100g/min in pig,
3
 2.7 mLO2/100g/min in rat
10
 and 3.7 
mLO2/100g/min in cat.
11
 Werkmeister and Co-workers
46
 have recently reported inner retinal 
oxygen extraction as 1.42 mLO2/min/100g tissue blood in humans. A inner retinal oxygen 
extraction of 1.42 mLO2/min/100g tissue blood, as discussed by the authors, is lower than might 
be anticipated.
46
 This value is almost half of what we have estimated in our study. The 
differences in RBF and blood O2 measurement techniques, variation in TRBF and SO2 analysis, 
as well as absence of direct measurement of certain variables in our study might also contribute 
to the estimated difference in O2 extraction value between the two studies. However, the baseline 
TRBF value in our study is 43.17 + 12.7 μL/min, which is comparable to 44.3 + 9.0 μL/min, as 
reported by Werkmeister and Co-workers.
46
  
Our data further shows that, inner retinal vessels demonstrate effective autoregulation during 
systemic hypoxia and hyperoxia studied i.e. TRBF significantly increased and decreased by + 
29.7% and -8.7% during PETO2 of 60 and 300 mmHg, respectively (Figure 4.3). Also, retinal 
blood SaO2 and SvO2  increased by +8.2% and +10.4% during hyperoxia (PETO2 of 300 mmHg); 
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two levels of systemic hypoxia significantly reduced the retinal blood SaO2 by -8% and -15% 
with a simultaneous reduction in SvO2 by -11% and -20%, during PETO2 of 60 and 50 mmHg, 
respectively (Figure 4.4).  
Limitations of the study include absence of direct measurement of certain variables. Alveolar 
oxygen tension (PaO2) was not measured; instead, PETO2 was considered as a surrogate for PaO2. 
However, previous studies report that PETO2 is a surrogate of the PaO2.
47
 Hemoglobin 
concentration and pH of the blood was not measured directly, instead, assumed to be 15 gm/dL 
and 7.4, respectively. Venous oxygen content (PvO2) was evaluated from arterial and venous 
partial pressure. The hemoglobin oxygen dissociation curve and the Hill equation were used to 
estimate PaO2 and PvO2 values from SaO2 and SvO2, respectively. A recent paper has 
quantitated the relationship between SaO2 and PaO2 using the Hill equation.
32
 Although the 
current study reports the simultaneous measurement of both TRBF and retinal blood SO2, two 
different techniques were used, so the measurement location of each parameter (i.e. TRBF and 
retinal SaO2 and SvO2) might differ slightly. Therefore future Doppler OCT instrument with in-
built oximetry for oxygen saturation measurement would be a major advancement.
48,49
  
The current study establishes baseline values of inner retinal oxygen extraction in healthy 
individuals during physiological perturbations of hyperoxia and hypoxia. Future studies will 
investigate the changes in these parameters in diseased eyes. The study concludes that despite the 
presence of changes in retinal blood flow and retinal blood SO2, during mild-moderate 
physiological perturbations of hypoxia and hyperoxia, inner retinal oxygen delivery and 
consumption was not significantly changed. Whether this remains true during severe hypoxic or 
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hyperoxic perturbation, as well as during the event of various retinal vascular pathologies needs 
further investigation.  
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Gas& Systemic 
Parameters 
(N=11) 
Normoxia 
PETO2=100 
mmHg 
 
Hyperoxia 
PETO2=300 
mmHg 
 
Hypoxia 
Stage 1 
PETO2=60 
mmHg 
 
Hypoxia 
Stage 2 
PETO2=50 
mmHg 
 
p value 
(reANOVA) 
 
RTVue 
PETCO2 
(mmHg) 
33.3 + 1.76 33.1 + 1.9 33.4 + 1.8 32.8 + 1.5 NS 
PETO2 (mmHg) 99.9 + 4.3 303.7 + 2.9 59.0 + 1.4 49.6 + 2.1 p=0.000 
SBP (mmHg) 116.5 + 8.8 117.8 + 7.6 115.4 + 7.5 115.2 + 9.7 NS 
DBP (mmHg) 75.3 + 4.3 77.3 + 4.9 77.4 + 6.6 74.6 + 6.2 NS 
HR (bpm) 71.9 + 7.2 68.4 + 5.6 77.6 + 7.3 81.8 + 10.2 p=0.000 
SpO2 (%) 98.7 + 0.8 99.6 + 0.4 89.9 + 2.4 84.6 + 6.1 p=0.000 
 
PETCO2 
(mmHg) 
33.1 + 1.6 32.6 + 1.4 33.1 + 1.7 33.0 + 1.6 NS 
PETO2 (mmHg) 100.0 + 1.6 301.9 + 2.3 60.3 + 1.4 50.2 + 1.1 p=0.000 
SBP (mmHg) 116.0 + 11.3 116.7 + 9.1 114.6 + 12.1 113.8 + 10.2 NS 
DBP (mmHg) 75.2 + 7.6 73.8 + 7.8 73.5 + 4.7 76.3 + 7.7 NS 
HR (bpm) 79.1 + 8.0 71.6 + 6.4 76.6 + 6.4 80.1 + 4.6 p=0.000 
SpO2 (%) 98.1 + 1.0 99.4 + 0.4 89.6 + 3.4 82.6 + 1.7 p<0.000 
HRC 
Table 4.1 Group mean (+SD) for gas and cardiorespiratory parameters across various levels of PETO2. 
(PETCO2-partial pressure of end-tidal carbon dioxide, SBP-systolic blood pressure, DBP-diastolic blood 
pressure, HR-heart rate, bpm-beats per minute, PETO2-partial pressure of end-tidal oxygen, SPO2-
peripheral capillary oxygen saturation). Note: NS denotes not significant; Level of significance was set to 
p<0.05. 
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Normoxia 
(PETO2=100mmHg) 
Hyperoxia 
(PETO2=300mmHg) 
Hypoxia1 
(PETO2=60mmHg) 
Hypoxia2 
(PETO2=50mmHg) 
p value 
(reANOVA) 
 
DO2 
(mLO2/100g/min) 
8.48 + 2.5 7.91 + 1.2 8.86 + 2.4 8.73 + 1.7 NS 
 
VO2 
(mLO2/100g/min) 
3.64 + 1.1 3.45 + 0.7 4.0 + 1.2 4.03 + 1.0 NS 
 
OEF 
 
 
0.43 0.43 0.44 0.45 NS 
Table 4.2 Inner retinal DO2, VO2 and OEF during normoxia, hyperoxia and hypoxia. 
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 Retinal Perfusion Changes in Radiation Retinopathy Post-Chapter 5
brachytherapy for Choroidal Melanoma 
5.1 Introduction 
Radiation retinopathy (RR) is a chronic progressive vasculopthy developing secondary to the 
impact of ionizing radiation to the retina.
1
 First described in 1933, the common retinopathic 
findings include hemorrhages, microaneurysms, cotton-wool spots, hard exudates, and retinal 
edema.
1,2
 Although progressive ischemia and proliferative changes mimics that of a fast 
developing diabetic retinopathy, their etiologies are different. RR develops post radiation therapy 
using radioactive plaque to treat intraocular tumors
3,4 
or external beam radiotherapy for head and 
neck cancers.
5
  
Plaque brachytherapy is the most popular treatment option for small to medium sized choroidal 
melanomas,
3,6,7
 with the larger tumors often managed by enucleation.
8
 Radioactive seeds 
containing 
125
Iodine are placed within a gold-shielded episcleral plaque, which then are 
surgically inserted at the tumor base. Though the plaque is removed from the eye within few 
days of insertion, the radiation dose delivered to the kill the tumor seems to have a significant 
impact on the surrounding healthy retinal tissues, especially blood vessels, which later manifest 
as progressive vasculoapathy.
3
 Pre-existing diabetes, hypertension, young age, and proximity of 
irradiated area to macula or optic nerve head all pose risk factors for retinopathy to develop in 
the irradiated eye.
3,9
 
The primary vascular event following radiation therapy is reported as endothelial cell loss 
followed by vascular occlusion and capillary drop out, which ultimately leads to vascular 
incompetence and retinal ischemia.
10
 The radiation significantly alters the structural and 
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functional aspects of the retinal microvasculature due to compromised blood-retinal barrier.
11
 
This process, however, could take up to months to years to develop as clinically visible 
retinopathy. It is not always predictable to discern those patients who develop RR. The available 
treatment options to this sight threatening condition are similar to those offered to other 
retinopathies, such as intravitreal anti- VEGF and intravitreal steroid agents.
12,13
  
Studies in the past have reported tissue hypoxia as a blinding mechanism underlying retinal 
vascular diseases such as diabetic retinopathy,
14,15,16
 central retinal artery and vein occlusion,
17,18
 
and glaucoma.
19,20,21
 Non-invasive spectral imaging of retinal blood vessels at wavelengths 
between 500-620nm is utilized in retinal oximetry by incorporating the differences in the spectral 
absorption characteristic of oxygenated and deoxygenated hemoglobin.
22
 Color coded maps of 
the retinal vascular tree provide qualitative and quantitative assessment of arteriolar and venular 
blood oxygen saturation.  
In our laboratory, Doppler SD-OCT and HRC are used to provide the non-invasive measurement 
of TRBF and SO2, respectively. The repeatability of these two techniques were previously 
analyzed under varying blood gas challenges and the results were published elsewhere.
23,24
 
Diabetic patients with early retinopathy who were previously evaluated using these two 
techniques showed lower TRBF and increased arteriolar and venular SO2.
14,25
 Also, retinal 
oximetry using HRC showed higher venular SO2 in patients with primary open angle glaucoma 
compared to controls.
19
 The results from our lab using these novel techniques are in general 
agreement with those reported by other investigators.
15,16,20
 The current study, for the first time, 
reports the retinal oxygenation and blood flow changes in early non-proliferative radiation 
retinopathy post 
125
Iodine brachytherapy.  
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5.2 Materials and methods 
5.2.1 Sample 
This study was approved by the University of Waterloo Office of Research Ethics, Waterloo, and 
by the University Health Network Research Ethics Board, Toronto. RR patients were recruited 
from the Ocular Oncology Clinic located at Princess Margaret Hospital, Toronto, Canada. Eight 
patients diagnosed with unilateral radiation related retinopathy (ischemic changes) as confirmed 
by wide-field fluorescein angiography in one eye (mean age 55.75yrs, SD 12.58 yrs) was 
recruited. All subjects were free from media opacity, diabetes, glaucoma, and other retinal or 
choroidal vascular disease. Exclusion criteria included intra-ocular pressure >21mmHg, history 
of ocular surgery, medications with known effects on blood flow except routine anti-
hypertensive medication (no change in prescription at least during past 6 months), history of 
cardiovascular diseases, stroke, myocardial infarction, diabetes, endocrine disorders, smoking, 
additional retinal diseases other than RR, previous trans-pupillary thermotherapy or external 
beam radiotherapy to either eye. Informed consent was obtained from each subject after a 
thorough explanation of the nature of the study and its possible consequences, according to the 
tenets of the Declaration of Helsinki. 
5.2.2 Study visit 
The study comprised a single visit, during which TRBF and SO2 measurements were taken one 
after the other in both eyes. The order of instrumentation was systematically varied between 
subjects. 
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5.2.3 Instrumentation 
5.2.3.1 Doppler SD-OCT, RTVue 
The Doppler SD-OCT (RTVue; Optovue, Inc., Fremont, CA, USA) is a novel prototype 
instrument with an inbuilt spectrometer that transmits wavelength of 841nm and a bandwidth of 
49nm. The axial and temporal resolutions are 5.6 µm and 20 µm, respectively in tissue. Double 
circular scans centered on the optic nerve head measure red blood cell velocity over a 
consecutive 2-second interval. About 3000 A-lines are sampled for each circular scan located at 
radii of 3.4mm and 3.75mm centered on the optic nerve head.
26
 The phase differences between 
the sequential A-lines are used to obtain the Doppler frequency shift (∆𝑓) of retinal blood cells, 
which can be derived as  
∆𝑓 = −2𝑛𝑉𝑐𝑜𝑠𝛼/𝜆0……………………………………………………………………  (5.1) 
where n is the refractive index of the medium, V is the velocity of the flow, 𝛼 is the angle 
between the flow and incident beam and 𝜆0 is the center wavelength of the light.
27 
 
A total of six scans were acquired for the TRBF measurements, where the blood vessels were 
identified as arterioles and venules based on the Doppler signal from the OCT images. Vessel 
area estimation was performed using a semi-automated software (version 2.1.1.4) named 
DOCTORC. A computer caliper was used to determine the cross sectional diameter of each 
retinal vessel within the Doppler OCT image.
28,29
 The estimated retinal vessel area along with 
the measured flow velocity gives the volumetric rate of blood flow for a given vessel in the scan. 
TRBF was calculated by summing the flow from all valid venules with detectable Doppler 
signal.
30,31 
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5.2.3.2 Hyperspectral Retinal Camera  
In this study, retinal blood SaO2 and SvO2 measurements were achieved using the HRC. The 
HRC (Optina Diagnostics, Montreal, Canada) is a prototype system comprising of a tunable laser 
source and custom made fundus camera. These two units are in turn connected to a computer that 
controls the image acquisition protocols, data storage and analysis. The inbuilt calibration system 
ensures the reproducibility of acquired spectral images at various ranges of pre-determined 
wavelengths. The inbuilt filters enable the acquisition of high resolution monochromatic fundus 
images, due to its capability of delivering monochromatic light at a narrow bandwidth of 2nm. A 
stack of data cubes containing spectral images are then generated within few seconds for the 
quantification of retinal blood SO2. The chosen wavelengths for retinal vessel oximetry are 
between 520nm-620nm at 5nm steps. Following the spectral image acquisition, the data cubes 
are then normalized and registered using PHySpec software (Photon etc, Montreal, QC, Canada). 
The technical details of normalization and registration are published previously elsewhere.
22
 An 
in-house Matlab (The Mathworks, Natick, MA) program is then used to open a pre-processed 
data cube in order to extract oxygen saturation data from retinal blood vessels. A single arteriole 
and venule is chosen along the superior or inferior temporal vessel arcade close to the optic nerve 
head for retinal blood SO2 measurement. The chosen vessel is then isolated from rest of the 
fundus image using an automatic vessel segmentation algorithm
32
 and the segmented vessel is 
analyzed further to derive the oxygen saturation along the retinal blood vessel.  
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5.2.4 Procedures 
During the subjects visit, logMAR visual acuity and intra ocular pressure (using the 
Goldmann Applanation Tonometer; Haag-Streit, Koniz, Switzerland) was recorded for both 
eyes. After making sure the blood pressure and pulse rate (Omron®) are within normal limits, 
both eyes were dilated with one drop of tropicamide 1.0% ophthalmic solution (Alcon, 
Mississauga, Canada). Upon pupil dilation, both eyes were imaged using Doppler SD-OCT 
and HRC. The order of instrumentation was systematically varied between subjects. 
5.2.5 Statistical analysis 
Statistica software (StatSoft, Inc., Tulsa, OK, USA) version 13.0 was used for analyzing the data. 
Two-tailed paired t-test was used to compare the results of the retinopathy eye and fellow eye. 
The level of significance was set to be p<0.05.  
5.3 Results 
A total of 8 patients diagnosed with RR in one eye were recruited for the study. The mean age 
was 55.75yrs, SD 12.58 yrs. All the study subjects were females. The average time since 
125
Iodine brachytherapy treatment  to the onset of retinopathy was 2.82 yrs, SD 1.29 yrs. 
LogMAR visual acuity in the eye with retinopathy was significantly lower compared to the 
fellow eye (0.63 + 0.36 vs 0.04 + 0.06, p=0.002). The average systolic and diastolic blood 
pressures of subjects were 132 + 15.72 mmHg and 86.25 + 9.52 mmHg, respectively. The mean 
heart rate was 73.12 + 15.04 beats/minute.  
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Retinal Hemodynamic measurements 
The subject’s retinal hemodynamic parameters are given in Table 5.1. TRBF in the eye with 
retinopathy was 33.48 + 12.73 µL/min, significantly lower compared to 50.37 + 15.26 µL/min in 
the fellow eye (n=8, p=0.013) as shown in figure 5.1. The venous area and venous velocity in the 
RR eye were found to be not significantly different compared to the fellow eye, 4.27 + 1.46 
(X10
2
mm
2
) vs 5.41 + 1.27 (X10
2
mm
2
) and 13.16 + 3.69 mm/sec vs 17.04 + 7.98 mm/sec, 
respectively. Retinal SaO2 was found to be significantly (p=0.008) increased in the retinopathy 
eye (101.11 + 4.26%) compared to the fellow eye (94.45 + 5.79%). Retinal SvO2 was found to 
be marginally higher in the affected eye (62.96 + 11.05%) compared to the fellow eye (51.24 + 
6.88%, p=0.051). Figure 5.2 shows the retinal blood SaO2 and SvO2 in retinopathy eye and 
fellow eye. 
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RR eye Fellow eye 
p value 
(paired t test) 
Vision 
(logMAR) 
0.63 + .36 0.04 + .06 p=0.002 
TRBF  
(µL/min) 
33.48 + 12.73 50.37 + 15.26 p=0.013 
Venous area  
(X10
2
mm
2
) 
4.27 + 1.46 5.41 + 1.27 NS 
Venous Velocity  
(mm/sec) 
13.16 + 3.69 17.04 + 7.98 NS 
SaO2 (%) 
101.11 + 4.26 94.45 + 5.79 p=0.008 
SvO2 (%) 
62.96 + 11.05 51.24 + 6.88 p=0.051 
A-V diff (%) 
38.14 + 10.9 43.21 + 8.82 NS 
Table 5.1 Comparison of vision and retinal hemodynamic parameters between radiation retinopathy eye 
and fellow eye. Paired t-test was used for statistical comparison. Level of significance was set to p<0.05. 
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Figure 5.1 Box plots showing total retinal blood flow (TRBF) of the RR eye vs Fellow eye. The 
legend in the middle of the box represent median, the upper and lower extremes of the box represent 
25th and 75th percentiles. Error bars on either side represent nonoutlier range. 
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Figure 5.2 Retinal oxygen saturation of arterioles (red) and venules (blue) in eye with retinopathy and 
fellow eye. Each dot represent mean oxygen saturation (%) along inferior or superior temporal retinal 
vessel located within 1 disc diameter of the optic nerve head. The horizontal line represents median and 
error bars on either side represent interquartile range.  
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5.4 Discussion 
A plethora of studies report altered retinal hemodynamics in patients developing retinopathy due 
to various diseases such as diabetes,
14-16,33
 hypertension,
34,35
, retinal artery  and vein 
occlusions.
17,18,36
 However, the current study is first to report retinal blood flow and SO2 changes 
in radiation induced retinopathy from plaque brachytherapy treatment for choroidal melanoma.  
Ionizing radiation has been reported to damage endothelial cells, cell membranes, organelles, and 
DNA.
10,37,38 
Histologically, retinal blood vessels have also been shown to exhibit similar changes 
as seen in irradiated tumor vessels.
39
 Radiation damage to blood vessels result in the form of 
intra retinal vascular leakage and edema due to vascular incompetence. The vulnerable vessels 
exhibit capillary wall narrowing and capillary drop out, thus causing localized ischemia and 
infarction.
2,10,11
  
Vascular endothelial cells are most vulnerable to radiation damage by losing their integrity of 
intercellular tight junctions, making the blood vessels more permeable to macro molecules and 
leakage of protein and fluids into the tissue.
10
 Free radical damage due to radiation is accentuated 
by the higher O2 tension at the arteriolar side of the retinal microvasculature and also due to the 
direct exposure of endothelial cells to the ionizing radiation. The developing retinopathy exhibits 
an early quiet phase of microvascular changes followed by an unpredictable and variable latent 
period.
10,40,41
  
The incidence of developing retinopathy following brachytherapy varies between studies. Two 
studies have reported a 2 year and 5 year incidence of retinopathy following 
125
Iodine 
brachytherapy as 30%
3
 and 52%,
42
 respectively. However, the incidence of RR is higher in 
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patients with diabetes.
3,43
 The advanced stages of retinopathy due to radiation damage can be 
painful as a result of ocular ischemia or neovascular glaucoma.
11,44
  
The current study reports increased retinal blood oxygenation and reduced blood flow in the eye 
developing RR. The decreased TRBF in RR could be from less demand by the tissue itself due to 
cell death or degeneration process as a result of radiation insult. This ultimately reduces O2 
demand and therefore lower flow. Also, the blood vessel wall thickening secondary to the 
deposition of fibrillary or hyaline material, post radiation could have narrowed the vessel lumen, 
thus allowing less blood to flow through the blood vessels. Roth and Co-Workers
41
 have 
previously reported decrease in retinal vessel diameter 30 days post radiation in experimentally 
irradiated hamsters. Our study shows a non-significant trend for reduced venous area in the eye 
with retinopathy compared to the fellow eye (4.27 + 1.46 X10
2
mm
2 
vs 5.41 + 1.27 X10
2
mm
2
). 
Substantial changes in retinal microcirculation could lead to compromised O2 distribution. In this 
study, retinal blood SO2 is found higher in the eye with retinopathy compared to fellow eye. 
Decreased O2 demand due to cell necrosis results in a proportionate decrease in O2 consumption, 
which explains the higher SO2 in retinal vessels. Another explanation for the altered O2 
distribution could be due that the capillaries have already lost their endothelial cells secondary to 
the radiation effect and this is thought to eventually collapse and occlude the vessel, while others 
vessels might dilate and appear telangiectatic.
2,10,11
 These dilated capillaries are thought to 
quickly shunt the blood bypassing the retinal arterioles and venules, thus leaving the tissue 
deprived of O2, leading to ischemia.   
Data pertaining to retinal blood flow and oxygenation in RR patients is very limited. More than a 
decade ago, two experimental animal studies reported the results of early (30 days) and late (180 
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days) ionizing radiation effects on the retinal circulation in the absence of retinopathy. Red blood 
cell velocity was reduced and vessel diameter was decreased following early radiation exposure 
in hamsters;
41
 the later study reported increased red blood cell velocity and increased capillary 
blood flow, as a late effect to the irradiated hamster retina.
40
  
Higginson and Co-workers
5
 reported altered retinal blood SO2 prior to any clinically visible 
retinopathy in patients who were treated with external beam radiotherapy for head and neck 
cancer. Also, they reported high within eye variability of SO2 measurements in nine irradiated 
patients compared to the controls. Our study shows increased retinal blood SO2 in patients who 
have already developed retinopathy post plaque brachytherapy for choroidal melanoma. The 
venular SO2 of the eye with retinopathy seem to show higher variability (62.96% + 11.05%) 
compared to the fellow eye (51.24% + 6.88%). One needs to be cautious in comparing the results 
between these two studies, since the radiation treatment type and the disease for which the 
patients were treated in the two studies are entirely different.  
Lack of a control group for comparison and smaller sample are possible limitations of this study. 
However, the data is first to report retinal hemodynamic changes in RR. The instruments used to 
measure retinal SO2 and blood flow are previously reported to be repeatable under various gas 
provocation challenges.
23,24
 The pathophysiology behind radiation induced retinopathy is studied 
to be microvascular in origin,
2,10,45
 however, the evidence is limited. Future work is to predict 
these ischemic changes at an early stage using current technologies, which might benefit the 
patient by availing current treatment options, such as intravitreal anti-VEGF, and to salvage the 
eye from this sight threatening vasculopathy. 
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 Increased Retinal Blood Oxygen Saturation Post Plaque Chapter 6
Brachytherapy for Choroidal Melanoma 
6.1 Introduction 
Choroidal Melanoma (CM) is the most common primary malignant tumor of the adult eye,
9
 and 
carries an overall mortality rate of 50% in developed countries.
7
 Reports predict that about six 
out of each million people will be diagnosed with CM in North America each year.
27
 Hispanics 
and Asians are thought to have a small but intermediate risk of acquiring CM compared to whites 
and blacks.
20,26
  
Primary CM arises from the melanocytes within the choroid. Three distinct cell types are found 
to be involved in the pathophysiology. They are spindle A, spindle B, and epitheloid cell types; 
of which the epitheloid cell type is more aggressive in behavior and carries a poor prognosis.
14
 
Malignant choroidal melanomas can metastasize to other parts of the body, with a survival rate 
of only 13%.
8
 Diagnosis of CM is based on the presence of characteristic clinical features such 
as tumor thickness, sub-retinal fluid accumulation and orange pigmentation over the tumor.  
Brachytherapy using radioactive plaques is considered as one of the most popular and preferred 
treatment of choice to treat CM.
18,19
 Although radiotherapy controls the tumor growth, the 
impact of ionizing radiation on the surrounding retinal vasculature was not understood until 
retinopathic changes emerged in the treated eye.
28
 The morphological retinal changes associated 
with RR resemble those of diabetic retinopathy but the rate of progression is far more rapid than 
diabetic retinopathy. Slowly proliferating tissues such as vascular endothelium, start manifesting 
radiation damage at a later stage. This predisposes changes in functional parameters of retinal 
microvasculature such as blood flow, velocity and vessel diameter.
21,24
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The effects of ionizing radiation on retinal vascular physiology are not well reported in literature. 
Our lab offers the facility to utilize two novel prototype instruments, i.e. the HRC and the 
Doppler incorporated SD-OCT to quantitate retinal blood SO2 and TRBF, respectively. These 
non-invasive tools may provide improved methods of predicting those who develop retinopathy 
following plaque brachytherapy, as well as to better understand the pathophysiology of RR. 
6.2 Materials and methods 
6.2.1 Sample 
This study was approved by the University of Waterloo Office of Research Ethics, Waterloo, and 
by the University Health Network Research Ethics Board, Toronto. CM patients were recruited 
from the Ocular Oncology Clinic located at Princess Margaret Hospital, Toronto, Canada. 
Seventeen patients diagnosed with unilateral CM (mean age 50.58yrs, SD 13.9yrs) were 
recruited. The subjects were free from media opacity, diabetes, glaucoma or any other retinal or 
choroidal disease except CM. Exclusion criteria included history of ocular surgery,  intra-ocular 
pressure >21mmHg, medications with known effects on blood flow except routine anti-
hypertensive medication (no change in prescription at least during past 6 months), history of 
cardiovascular diseases, stroke, myocardial infarction, diabetes, endocrine disorders, smoking, 
and previous trans-pupillary thermotherapy or external beam radiotherapy to either eye. 
Informed consent was obtained from each subject after a thorough explanation of the nature of 
the study and its possible consequences, according to the tenets of the Declaration of Helsinki. 
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6.2.2 Study visit 
The study was conducted in three visits. At the first visit, i.e. pre-treatment, TRBF and retinal 
blood SO2 was measured in both eyes. During visits 2 and 3, i.e. 3months and 6months post 
125
Iodine plaque brachytherapy, the measurements of TRBF and retinal blood SO2 were taken 
only from the treated eye. 
6.2.3 Instrumentation 
6.2.3.1 Doppler SD-OCT 
The Doppler technology incorporated SD-OCT (Optovue Inc. Freemont, CA, USA) enables the 
simultaneous measurement of absolute retinal blood velocity and venous area to derive TRBF, 
non-invasively.  The movement of red blood cells with in a blood vessel creates a “Doppler 
shift” within the reflected SD-OCT A-scan. The magnitude of Doppler shift depends upon the 
angle between the moving red blood cells and the reflected beam. A morphometric based 
algorithm named DOCTORC is utilized to determine the angle between the scanning laser beam 
and blood flow vector in order to measure absolute velocity.
29,30
 The velocity values are 
integrated from each blood vessel around the optic nerve head to determine the TRBF of the 
inner retina. 
The Optovue SD-OCT comprises a superluminescent diode, operating at a wavelength of 841nm 
and a bandwidth of 49nm. It has axial resolution of 5.6 μm and transverse resolution of 20 μm. 
The SD-OCT utilizes a Fourier transformation of the reflected signal spectrum for faster image 
acquisition. The interference pattern from the backscattered light is detected by a 1024-pixel high 
speed line-scan camera. Transformation of the spectral interference pattern gives a complex 
function of phase and amplitude. The phase difference between the sequential A-scans 
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determines the Doppler shift within the blood vessel. The technique is described extensively in 
various papers.
29,32-34
 
For TRBF measurements, four pairs of double circular scans that are approximately 3.40mm and 
3.75mm in diameter are taken over approximately two cardiac cycles for each measurement.
30,34
 
The scans are centered on the optic nerve head. The angle between the incident beam and the 
velocity direction of the blood, as well as the Doppler shifted frequency is used to determine the 
retinal blood velocity as given in the following equation 
∆𝑓 =
2𝑉𝑛𝑐𝑜𝑠𝜃
𝜆
……………………………………………………………………………………… (6.1) 
where, V is the velocity of the moving particle, 𝜃 is the angle between the OCT beam and the 
flow, n is the refractive index of the medium, and 𝜆 is the wavelength of the incident beam.  
The double circular scans enable the absolute blood velocity measurement through each and 
every vessel around the optic nerve head from the 3D OCT image. Semi-automated software 
named DOCTORC then allows for the identification of vessel type and location, to determine the 
venous area by subjective grading based on Doppler signal strength (Figure 6.1). Once the 
individual venous area is estimated, the flow from all the venules around the optic nerve head is 
then summed up to calculate the TRBF. 
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Figure 6.1 En face view of Doppler SD-OCT image with DOCTORC software identified vessel location 
(numbers) and type (red=artery; blue=vein). 
6.2.3.2 Hyperspectral Retinal Camera  
Hyperspectral retinal imaging determines the spectral absorption characteristics for a wide range 
of wavelengths ranging from 420 to 1000nm. It allows the two dimensional imaging for each 
specific wavelength to derive a measured data set called “image cube”, in which the third 
dimension represent the spectral absorbance value as a function of wavelength. The molecular 
content within the image is further determined based upon the spectral absorption spectra of 
well-established molecule such as hemoglobin. 
The instrument has an inbuilt mydriatic fundus camera and a tunable laser source (TLS).The 
TLS allows the rapid transmission of wavelength between 420 to 1000nm at a bandwidth of 
2nm.  The imaging Bragg Tunable Filter (i-BTF) technology (Photon etc), incorporated within 
the super-continuum light source allows for the precise and accurate wavelength selection 
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(<1nm). An in-built spectral power meter controls the temporary light fluctuations to enable 
uninterrupted image acquisition. The unique “non-flash” camera enables the high definition 
spectral imaging along 30 degree field of view. The TLS is controlled by software named 
PHySpec
TM
 (PHySpec
TM
, Optina, QC, Canada) for image acquisition and image post-processing. 
For retinal imaging, the chosen wavelength range from 520nm to 620nm. The time taken to 
generate a hyperspectral data cube i.e. a stack of 21 monochromatic fundus images was 80ms.
22
 
The acquired stack of data cubes are then loaded into the PHySpec
TM 
software for normalization 
and registration of images. The normalization generally corrects for image artifacts, while the 
registration corrects for eye movements and deformations due to imaging optics. After ensuring 
that the poor quality images are removed from further analysis, the remaining data cubes are then 
pre-processed using in-house Matlab software (The Mathworks, Natick, MA). An automated 
vessel segmentation algorithm is used to isolate the retinal vessels from the fundus background.
25
 
A major superior or inferior temporal vessel is chosen within 1 disc diameter of the optic nerve 
head for the SO2 measurement. The percentage of SO2 within the chosen vessel is automatically 
extracted from the optical density ratios using the well-established Hardarson‘s two-wavelength 
model.
12
 The Matlab software displays the color coded map of retinal arterioles and venules, 
where the colors represent the oxygen saturation within the retinal vessels. 
6.2.4 Procedures 
The CM patients scheduled to undergo 
125
Iodine plaque brachytherapy were recruited from the 
Ocular Oncology Clinic located at Princess Margaret Hospital, Toronto, Canada. After making 
sure the subjects fit within the study inclusion criteria, the subjects were scheduled for visit 1, i.e. 
a day before 
125
Iodine plaque brachytherapy treatment. During visit 1, subject’s cardiovascular 
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parameters such as blood pressure and heart rate were measured (Omron®). Following which, 
vision and intraocular pressure were recorded in both eyes, and then the pupils were dilated with 
one drop of tropicamide 1.0% ophthalmic solution (Alcon, Mississauga, Canada). Upon pupil 
dilation, both eyes were imaged using Doppler SD-OCT and HRC. The order of instrumentation 
was systematically varied between subjects. The patients were then scheduled for visits 2 and 3, 
i.e. 3months and 6 months post treatment. During visits 2 and 3, only the treated eye was imaged 
using Doppler SD-OCT and HRC following pupil dilation.  
6.2.5 Statistical analysis 
Statistica software (StatSoft, Inc., Tulsa, OK, USA) version 13.0 was used for analyzing the data. 
Paired t-test was used to compare the results of the untreated CM eye and fellow eye. A repeated 
measure ANOVA was used to compare the results between visits1 to 3 i.e. before, 3month and 6 
month post brachytherapy in the CM eye.  
6.3 Results 
A total of seventeen CM patients were recruited for the study. The mean age was 50.5 yrs, SD 
14.8 yrs (12 Males, 5 Females). Out of 17 CM patients recruited, 2 patient data was excluded due 
to poor image quality, and 3 others were lost to follow-up. Rest of the twelve subjects were 
followed up before, 3mth and 6 month post brachytherapy. The systemic and ocular 
characteristics of the CM patients during all the three visits are listed in table 6.1. 
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Untreated CM eye vs Fellow eye  
During visit 1, retinal hemodynamic parameters studied were not found to be significantly 
different in the untreated CM eye compared to the fellow eye (Table 6.2). A paired t- test was 
used to analyse the data. However, visual acuity was found to be significantly lower in the 
untreated CM eye compared to the fellow eye (p=0.01, Figure 6.2). Also, it was found that the 
smaller the tumor distance from the foveal avascular zone, the worse the visual acuity (r=-0.5, 
p<0.05) (Figure 6.3). 
  
 Visit 1 Visit 2 Visit 3 
p Value, 
reANOVA 
 
SBP (mmHg) 136.25 + 23.7 133.41 + 24.0 128.5 + 20.8 NS 
DBP (mmHg) 79.58 + 21.6 77.75 + 16.8 80.91 + 13.4 NS 
HR (beats/min) 75.25 + 10.1 72.58 + 13.8 76.12 + 12.7 NS 
LogMAR VA 0.31 + 0.3 0.40 + 0.3 0.44 + 0.4 NS 
Tumor Height (mm) 2.61 + 1.3 2.60 + 1.4 2.20 + 1.4 p=0.020 
Table 6.1 Group mean (+SD) for systemic and ocular characteristics across visits in CM patients. SBP-
systolic blood pressure; DBP-diastolic blood pressure; HR-heart rate; VA-visual acuity; NS-not 
significant. Level of significance was set to p<0.05. 
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CM Eye Fellow eye 
p value, 
Paired t test 
 
SaO2 (%) 93.87 + 8.1 93.80 + 8.4 NS 
SvO2 (%) 51.81 + 6.8 51.99 + 8.6 NS 
TRBF 
(µL/min) 
44.66 + 15.6 40.1 + 12.8 NS 
Venous area 
(×10
2
mm
2
) 
5.5 + 1.3 4.9 + 0.9 NS 
Venous velocity 
(mm/s) 
13.76 + 5.2 14.7 + 6.1 NS 
Table 6.2 Comparison of retinal hemodynamic parameters between untreated CM eye and fellow eye 
(n=15). Paired t-test was used for statistical comparison. Level of significance was set to p<0.05. 
 
Figure 6.2 Box plots represent visual acuity in CM eye vs Fellow eye. . The legend in the middle of the 
box represents the mean; the upper and lower extremes of the box represent 25th and 75th percentiles. 
Error bars represent the nonoutlier range. 
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Figure 6.3 Scatterplot of logMAR visual acuity to tumor distance from the foveal avascular zone. 
 
Retinal hemodynamic parameters pre- and post-brachytherapy 
The subject’s retinal hemodynamic parameters during visits 1 to 3 are given in table 6.3. Retinal 
arteriolar SaO2 significantly increased (reANOVA, p=0.026) from 94.4 % (+7.9) to 98.9% (+8.8) 
and 100.6 % (+6.4), respectively during 3 and 6 month follow up post 
125
Iodine plaque 
brachytherapy compared to before treatment (Figure 6.4). A post-hoc analysis for pairwise 
comparison was performed using Tukey’s HSD test. The results show that SaO2 was 
significantly increased only during 6month post treatment compared to pre-treatment (p=0.024). 
Regression plots for retinal SO2 measurements for each patient across all three visits are shown 
in figure 6.5. However, all the parameters including SvO2, TRBF, venous area, and venous 
velocity did not show a significant change across the visits (Table 6.3). The CM tumor height 
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was significantly reduced (reANOVA, p=0.020) 6 month post treatment compared to pre-
treatment (Figure 6.6). 
 
Visit 1 Visit 2 Visit 3 
p Value, 
reANOVA 
 
SaO2 (%) 94.11 + 7.8 98.93 + 8.8 100.6 + 6.4 p=0.026 
SvO2 (%) 52.53 + 7.3 52.37 + 9.1 55.19 + 9.9 NS 
TRBF 
(µL/min) 
43.00 + 16.8 40.44 + 9.2 46.57 + 15.03 NS 
Venous area 
(×10
2
mm
2
) 
5.84 + 1.3 5.29 + 0.8 5.14 + 0.9 NS 
Venous velocity 
(mm/s) 
12.29 + 4.0 12.8 + 2.8 15.4 + 5.6 NS 
Table 6.3 Group mean (+SD) for retinal hemodynamic parameters across study visits in CM patients. 
SaO2-arteriolar blood oxygen saturation; SvO2-venular blood oxygen saturation; TRBF-total retinal blood 
flow; NS-not significant. Level of significance was set to p<0.05. 
 
Figure 6.4 Box plots represent change in SaO2 across visits. The legend in the middle of the box 
represents the median; the upper and lower extremes of the box represent 25th and 75th percentiles. Error 
bars represent the nonoutlier range. Circle represents outlier. 
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Figure 6.5 Changes in retinal SaO2 (left) and SvO2 (right) across visits in all the twelve CM subjects. 
 
 
 
 
Figure 6.6 Group mean and error bars (+95% Confidence Intervals) showing changes in choroidal 
melanoma tumor height pre- and post- 
125
Iodine brachytherapy. 
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6.4 Discussion 
Brachytherapy using radioisotopes is one of the preferred treatments of choice to treat CM, due 
to its potential to preserve vison and salvage the eye, compared to other management options 
such as proton beam radiotherapy, helium ion therapy, stereotactic brachytherapy and 
enucleation.
5,19,17,37
 
125
Iodine brachytherapy emits relatively low energy photons, due to which 
radiation related complications are expected to be low. However, the treatment is known to be 
associated with complications such as keratitis, radiation cataract, neovascular glaucoma, 
retinopathy and optic neuropathy.
35
 
RR presents with microaneurysms, telangiectases, hard exudates, cotton wool spots, 
neovascularization and macular edema. Retinal capillary incompetence and closure are the 
earliest microvasculopathic changes reported.
2,6
 Radiation exposure to the surrounding healthy 
retinal vasculature other than tumor, leads to preferential loss of endothelial cells of the inner 
blood vessel lining and pericytes surrounding the blood vessels.  The direct exposure of radiation 
to the endothelial cells initiates high ambient oxygen and iron from blood as a result of free 
radical reaction due to ionizing radiation.
3
 The more severe form of retinopathy is characterized 
by the presence of neovascularization, vitreous hemorrhage, macular edema and tractional retinal 
detachment, secondary to retinal ischemia. The mean time to onset of proliferative RR following 
plaque brachytherapy was reported as 32 months, with younger age, pre-existing diabetes, closer 
tumor distance to fovea and optic nerve head having a higher predictability of proliferative RR.
4
  
Currently, the earliest these retinopathic changes could be identified is from fluorescein 
angiography; however, since the early signs are rarely symptomatic, the condition is mostly 
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diagnosed only during a routine follow-up visit. The present study reports earliest changes in 
retinal blood SO2, for the first time, in patients treated with 
125
Iodine plaque brachytherapy.  
The effect of single high doses of radiation on cerebral vasculature is manifested as significant 
reductions in regional cerebral blood flow and vessel length density, 3 weeks post treatment in 
rat retinae.
1
 Resch and Co-workers
23
 studied choroidal perfusion in eyes with untreated CM, and 
found no significant change in blood flow parameters between affected eye and unaffected 
contralateral eyes.   In contrast, another study reports higher pulsatile ocular blood flow in eyes 
with untreated CM.
36
 The central retinal artery blood velocity of the treated CM eye was found 
significantly reduced 6month, 12month and 24month post stereotactic radiotherapy.
31
 In our 
study, neither the blood velocity nor the flow was found significantly different pre- and post- 
treatment. In interpreting the results from these various studies, one needs to be cautious that the 
radiation dose and treatment type is entirely different between studies. Previous authors state that 
the untreated eye with CM may be expected to exhibit poor retinal perfusion in two ways, i.e. in 
untreated eyes due to “steal effect” of the blood towards the tumor and post-radiation, as 
secondary consequence to radiation effect.
31
 However, this result was not observed in the present 
work.  
Reduced red blood cell velocity and decreased vessel diameter was found in experimentally 
irradiated hamsters 30 days post radiation.
24
 Whereas, retinal blood velocity and capillary flow 
increased in the same animals 180 days post radiation exposure.
21
 These two studies report the 
early and late effects of ionizing radiation, indicating a slow and progressive impact of ionizing 
radiation on retinal hemodynamics. In the present study, although the blood flow seems to be 
increased from 43µL/min to 46.57 µL/min and blood velocity increased from 12.29 mm/s to 
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15.4mm/s, six month post brachytherapy, the results did not reach statistical significance.  The 
radiation dose used in the animal study and our study is different.  
Out of the twelve CM patients, one developed retinopathy during 6
th
 month follow-up. It is 
interesting to note that this subject had a steep increase in both SaO2 and SvO2 (approx. 20%) 
from a pre-treatment value of 84.9% and 47.6% to 107.3% and 71.6%, respectively, six month 
post brachytherapy (Subject 4 in Figure 6.5). Also, the same patient showed significant increase 
in TRBF from 52.9 µL/min (pre-treatment) to 64.8 µL/min (6month post treatment). This patient 
scenario is only used as an example to discuss but not to extrapolate this patient’s result in rest of 
the CM patients. 
Previous studies have reported that increased retinal SvO2 indicates reduced oxygen release to 
the tissue in the capillary bed, which could result in tissue hypoxia.
10,11,13
 The reduced oxygen 
extraction could be due to the various retinal microvascular changes such as capillary occlusion 
and formation of telangiectasiac vessels. The current study reports increased retinal arteriolar 
SO2 3month and 6month post brachytherapy. The absence of any previous studies reporting 
retinal blood SO2 in CM eyes post brachytherapy makes it difficult to compare the current results 
with that in literature.   
An increase in retinal arteriolar blood SO2 could be attributed to the improved retinal perfusion 
as a treatment response to brachytherapy. In another way, the radiation destroys the tumor cells, 
so the so called “steal effect” of the tumor is expected to not exist, thus retinal tissue perfusion 
increases post brachytherapy. In the long run, we might expect the same increasing trend in both 
the retinal arteriolar and venular blood SO2, due to the fact that capillaries might slowly (over 
years with peak effect about 3 years post treatment) lose their endothelial cells and pericytes and 
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occlude secondary to the effects of radiation. Decreased O2 demand due to cell necrosis results in 
a proportionate decrease in oxygen consumption, which might cause higher SO2 in retinal vessels 
especially in venules, despite underlying ischemic insult. The radiation dose, proximity of the 
tumor to foveal avascular zone, young age and pre-existing diabetes are some of the 
determinants for the time of onset, rate of progression and severity of retinopathy.
16
 The unique 
clinical pattern and unpredictable latency of radiation retinopathy is related to the life cycle of 
the retinal vascular endothelial cell.
2,3
  
One of the major limitations of the current work is the small number of subjects followed-up. 
This could be avoided in future studies by recruiting a higher volume of patients. A retrospective 
chart review will be conducted in the patients recruited so far to follow-up on the retinopathic 
changes. Predicting who will develop RR from the retinal blood SO2 changes require more 
patient data in order to reach a conclusive result. This will be addressed in future work. 
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 General Discussion Chapter 7
The retinal tissue offers unique opportunity to directly observe its microvasculature non-
invasively. This has led to the development various non-invasive techniques to quantify retinal 
blood flow. Previous measurement techniques such as blue field entoptic technique, retinal 
vessel analyzer, gave only a surrogate measure of flow. The introduction of Doppler techniques 
to measure red blood cell velocity within retinal vessels has revolutionized the field of objective 
retinal hemodynamic assessment. Doppler incorporated OCT offers the volumetric measure of 
TRBF at a single point in time. This technique surpasses the limitations of other previously 
introduced laser Doppler techniques such as Canon laser blood flowmeter which could measure 
blood flow from a single vessel at any one point in time.
1-3
  
Though the repeatability and variability parameters still need to be improved for the Doppler 
Spectral Domain OCT (SD-OCT) technology to be utilized in a clinical setting, it remains to be 
the only prototype currently available, that is capable of measuring TRBF in a single 
measurement. Chapter 3 details the repeatability and variability of Doppler SD-OCT under 
varying systemic oxygen concentrations. Overall, the coefficient of repeatability tends to be 
moderately high relative to a mean effect; however, the Doppler SD-OCT gave consistent and 
reliable measurements of blood flow during systemic changes in PETO2 in normal healthy 
individuals.  
Retinal blood supply is tightly regulated under various hemodynamic considerations.
4
 Changes 
in light stimulation, blood gas concentration, intra ocular pressure, and systemic blood pressure 
are all have known to reciprocate changes in blood flow and vascular resistance.
5-8
 Impairment 
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of retinal vascular reactivity per se has been reported in retinal vascular diseases such as diabetic 
retinopathy, glaucoma, and even in young healthy smokers.
9-12
 
In chapter 3, the novel gas provocation utilized, allows the precise combinations of PETO2, while 
clamping the PETCO2, or vice versa, provides reliable and reproducible measure of vascular 
reactivity. Previous techniques were unable to independently control PETO2 and PETCO2;
13,14
 but 
instead used 100% O2 or coadministerd O2 (~>90%) and CO2 (~5%), without clamping the 
PETCO2.
15,16
 This could impact the results of the measured retinal vascular response.
22
 The 
automated gas flow controller detailed in chapter 3, controls the subject’s minute CO2 production 
and O2 consumption, gas flow and composition entering the sequential gas delivery circuit. This 
standardized gas provocation technique is utilized to calibrate the Doppler based retinal blood 
flow measurements using SD-OCT and HRC derived retinal arteriolar and venular blood SO2 
measurements. The calibration of gas provocation unit is undertaken once a day using reference 
gases of known combinations of O2, CO2, and N2 (Nitrogen). 
 
Measurement of retinal blood SO2 was once possible only by using invasive techniques such as 
oxygen sensitive microelectrodes to study the oxygen tension of the inner retina.
17-19
 In contrast, 
the recently introduced spectral imaging technology represents a substantial advance in terms of 
non-invasive assessment of retinal blood SO2. The HRC is a non-invasive prototype system 
which allows the measurement of retinal arteriolar and venular blood SO2. Compared to the 
“snap-shot” systems, which could bleach the retinal photo pigments, the HRC has a “non-flash” 
camera, which makes it unique compared to other oximetry techniques available elsewhere. As is 
common in other retinal oximetry techniques, some arteriolar blood SO2 values were above 
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100%, which is beyond the physiological range. At this point, it is unsure whether this could be 
due to the error in terms of SO2 calculation itself or secondary to poorly registered images. 
However, the images included for the analyses in this thesis were carefully selected and 
examined before calculating SO2. 
The variability reported (chapter 3) for both the prototype techniques of Doppler SD-OCT and 
HRC, could be attributed to the subjectivity in terms of blood flow analysis and Doppler signal 
differences between visits as well as few imperfections in the optics design of the HRC, 
respectively. Improving such aspects could greatly reduce the variability and improve the 
repeatability of these two novel techniques to be utilized clinically.  
By measuring the retinal blood flow and blood SO2, in chapter 4, inner retinal oxygen extraction 
was calculated  using Fick’s principle which is the product of TRBF and arterial-venous oxygen 
content difference (CaO2-CvO2). Measurement of retinal O2 extraction could bring forth a clearer 
understanding of the retinal health in disease. However, these measurements were not made 
simultaneously at the same vessel, same location and at the same time, instead measurements 
were acquired sequentially. Future OCT technology with in-built Doppler blood flow and retinal 
oximetry methodologies
20,21
 would be a major advancement.  
We decided to apply these novel methods in the CM patients undergoing brachytherapy 
treatment because RR is one of the common sight-threatening complications following radiation 
treatment such as brachytherapy for CM. Also, it is interesting that the RR presents clinically 
similar to a fast developing diabetic retinopathy. Whether or not ionizing radiation impacts the 
retinal vasculature remains to be an interesting question to answer. 
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Therefore, in chapter 5 I investigated the impact of brachytherapy on retinal blood flow and 
oxygen saturation. RR patients were recruited from the Ocular Oncology Clinic located at 
Princess Margaret Hospital, Toronto, Canada. In this study, reduced TRBF and increased retinal 
blood SO2 was found in the eye with RR compared to the fellow eye. The reported higher retinal 
blood SO2 in the retinopathy eye could be secondary to decreased oxygen demand due to cell 
necrosis. The decreased TRBF in RR could be from less demand by the tissue itself due to cell 
death or degeneration process as a result of radiation insult. These results indicate an altered 
retinal vascular physiology in patients with radiation related retinopathy. Lack of a control group 
for comparison and a small sample size are possible limitations of this study. However, the data 
is first to report changes in retinal blood SO2 in radiation induced retinopathy and this sample of 
patients with RR is the largest prospective group that we are aware of in the literature.  
Chapter 6 detailed the changes in retinal blood SO2 in CM patients before and after 
brachytherapy treatment. The ultimate aim is to derive a model to predict retinopathy form the 
changes in retinal oximetry, which seem to be a precursor to tissue hypoxia in diseases such as 
diabetic retinopathy. It is interesting to note that the RR clinically presents similar to a rapidly 
developing diabetic retinopathy. 
CM patients were recruited from the Ocular Oncology Clinic located at Princess Margaret 
Hospital, Toronto, Canada. This remains to be the only center in Canada to treat CM patients 
using plaque brachytherapy. The study reports increased retinal arteriolar blood SO2 post 
125
Iodine brachytherapy for CM. Predicting who will develop radiation retinopathy from the 
retinal blood SO2 changes observed requires a longer follow-up period in order to reach a 
conclusive result. This work is in progress. 
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7.1 Future direction 
Improvement of the Doppler SD-OCT and HRC technologies is needed in order to reduce the 
variability, which could make these prototype techniques less demanding clinically. In terms of 
the HRC, the imperfectible optics design of the retinal camera causes a number of image artifacts 
that cannot be completely corrected in image processing steps, which excludes such images. The 
automation of blood flow analysis and a faster scan rate would also reduce the variability. The 
Doppler SD-OCT is reported to have a coefficient of variability of 15.1% in young healthy 
participants. The repeatability could be worse in elderly population, where maintaining steady 
fixation and controlling eye movement could be more challenging. The retinal blood SO2 
reported in this study is from one single arteriole and venule, whereas, deriving the SO2 for the 
whole of the vascular tree would be undoubtedly beneficial.  
Longitudinal studies that could track changes in retinal blood SO2 are important to better 
understand the impact of ionizing radiation in the progression of RR. A larger sample must be 
recruited since these patients experience significant psychological trauma as a result of the 
diagnosis, and therefore are easily lost to follow-up. Along with the retinal SO2 measurement it 
would be worthwhile to investigate the level of inflammatory biomarkers such as VEGF at 
different stages of progression of radiation retinopathy to better understand the pathogenesis 
behind the latency and variability in developing retinopathy. 
In summary, the variability and repeatability of two novel prototype techniques of Doppler SD-
OCT and HRC are reported under varying blood gas perturbations using standardized gas 
provocation methodology.  
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These two protype techniques are further utilized in the assessment of retinal perfusion changes 
in RR for the first time, where the ionizing radiation used to treat CM seems to have an impact 
on retinal vascular physiology. 
The effect of brachytherapy treatment on retinal vasculature is studied longitudinally, except that 
the results of the initial six months post treatment are presented in this work. Interestingly, retinal 
blood SO2 increases significantly post brachytherapy in CM patients. Further follow-up to 
predict who will develop RR will be continued in future work. 
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